# "Actionable" Risk for Preterm Birth: Patterns and Prediction in California Singleton Births 2016-2020

Laura L. Jelliffe-Pawlowski[1-8] (HOPE Lab: Rebecca J. Baer[2,3,6-11] Scott Oltman,[1,4-7] Safyer McKenzie-Sampson,[7,12] Deborah Adeyemi,[4,7] Ashley Becker,[7] Kacie C.A. Blackman,[7,14] Bridgette Blebu,[7,15] Justin S. Brandt,[2,3,7] Elena Flowers,[7,16] Dana R. Gossett,[2,3,7] Emily C. Hanselman[19], Sasha Hernandez,[2,3,7] Liang Liang,[7,17] Audrey Lyndon,[1,7] Allison M. Momany,[7,18] Elizabeth E. Rogers,[7,10] Kelli K. Ryckman,[7,19] Louie M. Swander,[7,10] Karen M. Tabb,[7,20] Kelly D. Taylor,[6,7,21] Sophia L. Wiggins,[7] Akila Subramaniam,[7,22]

[1]Rory Meyers College of Nursing, New York University, New York, New York

[2]Department of Obstetrics & Gynecology, Grossman School of Medicine, New York University, New York, New York

[3]Department of Obstetrics & Gynecology, New York University Langone Health, New York, New York

[4]Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California

[5]Department of Global Health Sciences, University of California San Francisco, San Francisco, California

[6]The California Preterm Birth Initiative, University of California San Francisco, San Francisco, California

[7]Healthy Outcomes of Pregnancy for Everyone (HOPE) Research Consortium, University of California San Francisco, San Francisco, CA; New York University, New York, New York

[8]UCSD Study of Outcomes in Mothers and Infants (SOMI), La Jolla, CA

[9]Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California

[10]Department of Pediatrics, University of California, San Francisco, San Francisco, California

[11]Department of Pediatrics, University of California San Diego, La Jolla, California

[12]Department of Health Behavior and Health Equity, School of Public Health, University of Michigan, Ann Arbor, Michigan

[13]Department of Family Community Medicine, University of California, San Francisco, San Francisco, California

[14]Department of Health Sciences, California State University Northridge, Northridge, California

[15]Department of Obstetrics and Gynecology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA

[16]School of Nursing, University of California San Francisco, San Francisco, California

[17]Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin

[18]Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa

[19]Department of Epidemiology and Biostatistics, School of Public Health-Bloomington, Indiana University, Bloomington, Indiana

[20]School of Social Work, University of Illinois Urbana-Champaign, Urbana, Illinois

[21]Department of Medicine, University of California, San Francisco, San Francisco, California

[22]Department of Obstetrics and Gynecology, University of Alabama Birmingham, Birmingham, Alabama

**Abstract**

Background

Preterm birth (PTB, <37 weeks of gestation) is the leading cause of child mortality in the United States (U.S.) and worldwide, and has substantial short- and long-term health consequences for mothers and infants. Each year, >350,000 infants in the U.S. are born preterm, and rates continue to rise in parallel with maternal risk factors such as hypertension, diabetes, anemia, asthma, and mental health conditions. Evidence-based interventions exist for many of these conditions and are associated with improved pregnancy outcomes, including low-dose aspirin for preeclampsia prevention in individuals with chronic hypertension or pregestational diabetes, inhalers for asthma, iron for anemia, and therapy or medication for mental health disorders, but fewer than half of eligible individuals receive them, reflecting persistent gaps in use. To address this, we developed the PTB Actionable Risk Index (PTB-ARIx), which leverages factors with known evidence-based interventions to identify individuals who are pregnant and are at increased risk for PTB. This study evaluates performance of the PTB-ARIx throughout pregnancy in terms of risk determination and characterization of actionable risk factors, including their combined contributions to PTB.

Methods and Findings

A retrospective cohort study was conducted using linked data for 1.9 million singleton live births in California in 2016-2020, divided into training and testing sets. Poisson regression estimated associations between 18 candidate risk factors for PTB with evidence-based interventions spanning clinical, behavioral, and social risks, including preeclampsia risk composites (≥1 high-risk or ≥2 moderate-risk factors based on U.S. Preventive Services Task Force (USPSTF) criteria), maternal conditions (e.g., gestational hypertension, asthma), substance use, and social adversity. Beta coefficients were combined to construct the PTB-ARIx, evaluated by per-unit associations with PTB and by area under the receiver operating characteristic curve (AUC) overall, by early (<32 weeks), late (32-36 weeks), spontaneous, and medically indicated PTB, and by PTB co-occurring with preeclampsia.

All risk factors were found to be associated with increased PTB risk. Having ≥1 high-risk or ≥2 moderate-risk factors for preeclampsia (based on composites) was most strongly related to PTB (relative risk (RR) 6.73, 95% confidence interval (CI) 6.57, 6.89). Each unit increase in PTB-ARIx was associated with >60% higher PTB risk (RRs 1.66–1.72) across training and testing samples, with consistent findings across PTB and race/ethnicity–insurance subgroups. Model performance was modest for late PTB (AUC ≈0.63), stronger for early PTB (0.69–0.72), and especially high for early PTB

with preeclampsia (AUCs up to 0.97). Over 70% of individuals with PTB-ARIx scores ≥3.00 experienced PTB or another adverse outcome such as low birth weight (<2500 grams).

Conclusions

The PTB-ARIx is a well-performing metric for identifying individuals at increased risk for PTB and other adverse pregnancy outcomes. By centering on modifiable risks, the PTB-ARIx combines risk identification with opportunities for intervention. Demonstrating strong performance across subgroups, including for early PTB and PTB with preeclampsia, the PTB-ARIx provides a potential pathway to improve patient–provider communication and uptake of equitable, evidence-based care. Further validation, including integration with treatment data, is needed to confirm its potential to reduce PTB risk and rates.

**Author Summary**

**Why was this study done?**

- Preterm birth (PTB), or delivery before 37 weeks of pregnancy, is a leading cause of newborn illness and death worldwide, and rates are rising in parallel with increases in known risk factors like hypertension, diabetes, asthma, anemia, and mental health conditions.

- Effective, evidence-based treatments for known PTB risk factors are underutilized.

- Many existing tools predict PTB using statistical thresholds but do not highlight risk factors with proven treatment(s) or intervention(s) during pregnancy.

- There is a need for approaches that both predict PTB and link directly to actions that can reduce risk.

**What did the researchers do and find?**

- We used health data from more than 1.9 million births in California to develop the Preterm Birth Actionable Risk Index (PTB-ARIx).

- The PTB-ARIx included 18 risk factors grouped into: (1) composite preeclampsia risk groups (≥1 high-risk factor or ≥2 moderate-risk factors, as defined by U.S. Preventive Services Task Force guidelines), (2) maternal medical conditions (such as prior PTB, gestational diabetes, asthma, and anemia), (3) infections and reproductive health (such as sexually transmitted or urinary tract infections), (4) behavioral risks (such as smoking and substance use), and (5) social and care-related risks (such as food insecurity, and housing instability).

- The PTB-ARIx showed consistent performance in predicting different types of PTB, including early PTB and PTB with preeclampsia, with similar performance across race/ethnicity and insurance groups.

- We also found that the number of prenatal visits partly explained some of the relationship between risk scores and outcomes, suggesting that regular care may play a role in mitigating PTB risk.

**What do these findings mean?**

- The PTB-ARIx provides a new way to predict PTB that highlights risk factors where preventive treatments or interventions, such as aspirin for individuals at increased risk of preeclampsia, can be applied during pregnancy.

- This model may help providers and patients work together to better identify, understand, and reduce risk, supporting more equitable care across diverse populations.

- Further research is needed to test the tool in other settings, study how treatments affect risk, and evaluate whether a patient-facing version can improve uptake of interventions and pregnancy outcomes.

**Introduction**

Preterm birth (PTB), birth before 37 weeks of gestation, is the leading cause of child mortality in the United States (U.S.) and globally [1,2]. Each year, there are more 350,000 PTBs in the U.S. [3], driving health care costs that exceed $25 billion [4]. Despite decades of research investment and clinical focus [5], PTB rates have increased. Between 2016 and 2023, the PTB rate among singleton births rose from 8.0% to 8.7% in the U.S. [3].

PTB carries profound health consequences for both pregnant individuals and infants. Individuals who deliver preterm face higher risks for postpartum infection, preeclampsia, and severe maternal morbidity (SMM) [6-9], as well as elevated long-term risks for cardiovascular and renal disease, cancer, and all-cause mortality [10-17]. Infants born preterm are at increased risk of neonatal and infant death [2,18,19] and, as they age, are more likely to develop chronic conditions such as asthma, diabetes, hypertension, and stroke [20-25]. They also may experience elevated risks for neurodevelopmental delays and mental health disorders, including anxiety and depression, that may develop during childhood and adolescence and persist throughout adulthood [26-32].

The burden of PTB is unequally distributed and closely tied to social determinants of health (SDoH), including race and ethnicity, income, and other factors related to structural determinants due to policies and income inequities. Disparities in outcomes among individuals who give birth preterm and those who give birth at term, and their infants, have continued to widen, particularly at the intersection of geography, race/ethnicity, and income [3,33,34-37].

Inequities in the burden of PTB extend beyond delivery. Low-income Black/African American individuals who deliver preterm are more likely to experience SMM [36], while their infants face higher risks for bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and mortality, even when born at similar gestational ages as infants from other groups [37].

<u>Risk Factors, Evidence-Based Interventions, and Underutilization</u>

Growing evidence links rising rates in key risk factors to both the overall increase in PTB and widening inequities. In a study of more than 5.1 million singleton births in California from 2011–2022, PTB rates were found to have climbed from 6.8% to 7.5%, a 10.6% relative increase [34]. This increase mirrored sharp upticks in chronic and gestational hypertension, preexisting and gestational diabetes, prior PTB, obesity, asthma, anemia, autoimmune diseases, infections complicating pregnancy, mental health conditions, substance use, and housing insecurity across race, ethnicity, and insurance status [34]. The study also found that some of the largest increases in the prevalence of risk factors were

concentrated in populations already experiencing PTB disparities. For instance, from 2016–2022, gestational

hypertension rose 51.8% (from 8.5% to 12.9%) in non-Hispanic (NH) Black/African American individuals with MediCal

(California's Medicaid) and 103.9% (from 7.7% to 15.7%) in those without MediCal [34]. National CDC data show similar

trends: between 2016–2023, gestational hypertension rates rose 60.5% (from 7.2% to 11.5%) in NH Black/African

American individuals with Medicaid and 62.3% (7.1% to 11.5%) in those without Medicaid [3,35].

While several evidence-based interventions targeting risk factors closely linked to PTB have been shown to reduce

the risk of PTB and improve birth outcomes, uptake remains suboptimal across multiple risk factors and groups

(Supplementary Table 1) [38-165]. Recommended interventions that may be prescribed by providers include, for

example, the use of low-dose aspirin after 12 weeks' gestation for individuals with preexisting diabetes or chronic

hypertension as preeclampsia prophylaxis in pregnancy [38]; pharmacologic management of asthma [72]; and

therapeutic and/or pharmacologic treatment for mental health conditions during pregnancy [125-127]. Documented

gaps in utilization are large. Multiple independent studies have highlighted low uptake of evidence-based interventions

among pregnant individuals with specific risk factors. In one study, only 57% of those at high risk for preeclampsia (e.g.,

preexisting diabetes, chronic hypertension, or prior preeclampsia) received low-dose aspirin [40]. In a separate study of

pregnant individuals with asthma, just 32% reported use of inhalers or other medications [75]. Another study found that

among those with a diagnosed mental health condition, as few as one in three (33%) received treatment [135].

Marked disparities have also been observed in evidence-based intervention use across race/ethnicity and

socioeconomic groups. In one study, the use of continuous glucose monitoring (CGM) among individuals with type 1

diabetes was found to be 31.1% in those covered by private insurance, compared to 9.6% among those with public

insurance [44]. In another study, treatment rates for mental health conditions during pregnancy ranged from 19.1%

among NH Black/African American individuals to 40.7% among NH White individuals [135].

Creating an Actionable Risk Index for Preterm Birth: Closing "Know-Do" Gaps

Rising rates of PTB [1,3], growing prevalence of associated risk factors [34,35], and the persistent underutilization of

evidence-based interventions (sometimes referred to as "know-do gaps" [166]) underscore the urgent need for more

effective strategies to identify and respond to risk. Critically, the consistently low uptake of interventions known to

improve maternal health and reduce the risk of PTB and related complications, such as preeclampsia, represents a

missed opportunity for both prevention and protection, particularly in groups experiencing health inequities. These gaps

offer clear inroads for strategies that may hold particular promise for improving the uptake of evidence-based interventions and ultimately reducing PTB rates in those at the highest risk.

One such opportunity lies in the development and implementation of an actionable PTB risk index for patients and providers, an approach that considers clinical, behavioral, and social risks with related evidence-based interventions. Such an index could be used to assist in discussions of risk and related interventions between pregnant people and their providers. Shifting toward a risk identification framework rooted in actionability would mark a departure from current prenatal care practices, where formal PTB risk scoring is rarely used. Some prenatal care providers have expressed reluctance to discuss elevated PTB risk without having clear, evidence-based interventions to offer, citing concerns that such conversations could increase patient anxiety, foster blame, erode trust, or reinforce a culture of risk [167,168]. In contrast, patients have reported valuing transparency about risk for PTB and other adverse outcomes, even in the absence of definitive treatments, to feel informed, prepared, and more actively engaged in their care [167,169-172]. This disconnect may help explain why existing PTB prediction tools [173-178], particularly those that emphasize nonmodifiable factors or rely on inputs with limited translational value, have seen limited uptake in clinical settings.

Focusing on actionable risks that can be addressed during pregnancy may help bridge this communication divide. Such a focus has the potential to facilitate earlier and more targeted uptake of evidence-based interventions, improve communication between patients and providers, and ultimately reduce the risk of PTB and other closely linked outcomes (e.g., preeclampsia, low birth weight (LBW; <2500 grams)). This approach also aligns with recent calls from the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) to adopt care models that incorporate medical complexity, psychosocial context, and patient preferences [179-181]. Both organizations have issued calls to expand the use of proven interventions, particularly among high-risk and underserved populations [182,183]. Importantly, a focus on actionable risk does not negate the relevance of molecular, genetic, or other biologic pathways for PTB prediction [184-186]; rather, it emphasizes that optimizing the use of known, effective interventions in response to modifiable risk represents an essential and scalable starting point.

In this context, our objective in the present study was to develop and evaluate a Preterm Birth Actionable Risk Index (PTB-ARIx) using data from over 1.9 million births in California between 2016 and 2020. The PTB-ARIx was developed to identify and stratify pregnant individuals based on actionable risk factors. We evaluated model performance across PTB subtypes, including spontaneous, medically-indicated, early (<32 weeks), and late (32–36 weeks) PTB, as well as for PTB

co-occurring with other adverse outcomes, such as preeclampsia and/or LBW. We also examined care engagement

indicators, including timing of prenatal care initiation and number of visits, as potential risk modifiers. Model

performance and potential effect modification were assessed overall and within key sociodemographic subgroups with

the goal of informing the development of an equity-oriented clinical tool that improves PTB risk identification and

facilitates the uptake of targeted, evidence-based interventions, particularly in those at highest risk.

**Methods**

Study Design and Population

We conducted a retrospective population-based cohort study of singleton live births in California from January 1,

2016, through December 31, 2020. The initial sample included 2,290,649 live births and was restricted to those with

gestational ages from 22 to 42 weeks (n = 2,280,142), who were singletons (n = 2,209,857), and had linked birth

certificates and pregnant-person/infant hospital discharge records for the birth (n = 1,907,085) (Supplemental Figure 1).

Records were derived from California birth certificates maintained by the California Department of Public Health-Vital

Records [187], with linkage to pregnant-person and infant hospital discharge records maintained by the California

Department of Health Care Access and Information (HCAI) [188]. Linkage was performed using deterministic and

probabilistic algorithms (as described in Baer and colleagues [189]) and achieved a linkage rate of 86.3%. The cohort was

split into a training sample (births from 2016–2019; n = 1,568,976) and a temporally distinct testing sample (births from

2020; n = 338,109).

Risk Factors and Predictor Variables

The study examined associations between PTB and 18 actionable clinical, behavioral, and social risk factors (17

single risk factors along with composite risks for preeclampsia), selected for their established links to PTB and the

availability of potential evidence-based interventions (Table 1). All variables were derived from birth certificates and/or

maternal or infant hospital discharge records, with ICD-10 coding applied where applicable [190,191] (see Supplemental

Table 2). Risk factors were modeled as dichotomous variables, except for composite indicators related to elevated

preeclampsia risk, which were constructed in alignment with the U.S. Preventive Services Task Force (USPSTF)

recommendations for aspirin use in pregnancy [38]. Based on task force recommendations [38], individuals were

classified as: 1) having one or more high-risk factors for preeclampsia (pregestational diabetes [type 1 or 2], chronic

hypertension, kidney disease, or autoimmune disorders [e.g., systemic lupus erythematosus, rheumatoid arthritis]) only

(not having two or more moderate-risk factors for preeclampsia); 2) having two or more moderate-risk factors for preeclampsia (nulliparity, obesity [pre-pregnancy body mass index [BMI] ≥30 kg/m²], advanced maternal age [>34 years], prior adverse pregnancy outcome [e.g., miscarriage, stillbirth, or PTB], interpregnancy interval [IPI] >10 years, conception via in vitro fertilization [IVF], low income [proxied by public insurance enrollment], and/or Black/African American race or ethnicity, and not having one or more high-risk factor for preeclampsia); or 3) having at least one high-risk factor and two or more moderate-risk factors.

These composite variables were further evaluated to examine the relationship between PTB and the number of high-risk and/or moderate-risk factors present modeled as continuous predictors. Of note, prior preeclampsia and family history of preeclampsia (e.g., in a mother or sister), while included in the task force guidelines, are not captured in California birth certificates or hospital discharge records and were therefore excluded from the present analysis. Each of the following risk factors was assessed individually as a binary yes/no variable based on the presence of an ICD-10 diagnosis present in the hospital discharge record [191] (see Supplemental Table for coding): gestational diabetes, gestational hypertension, asthma, anemia (non-sickle cell), sickle cell anemia, malignancy or active cancer diagnosis, sexually transmitted infection (STI, e.g., syphilis, chlamydia, human immunodeficiency virus [HIV]), other infections (e.g., urinary tract infection [UTI], influenza, COVID-19), sleep disorders (e.g., insomnia, obstructive sleep apnea), mental health conditions (e.g., depression, anxiety, bipolar disorder), tobacco use (smoking or vaping), cannabis (marijuana) or other drug use, alcohol use, homelessness or housing insecurity, and exposure to intimate partner violence or domestic violence.

Although there is an ICD-10 code that captures food insecurity [191], it is not consistently used across California hospitals and as such, while it was included in the conceptual framework for the predictive metric given its consistent association with PTB and the demonstrated efficacy of interventions such as food assistance in reducing risk [136,159-161], specific risk-related associations between food insecurity and outcomes are not provided.

Other Included Variables

Maternal sociodemographic characteristics evaluated included age, race/ethnicity (as self-reported on the birth certificate), education level, and nativity (U.S.-born vs. foreign-born). Race/ethnicity was coded as: Hispanic or NH (where Hispanic = Central or South American; Cuban; Mexican, Mexican American, or Chicano; Puerto Rican; or other Spanish or Hispanic ethnicity), American Indian or Alaska Native, Asian, Black, Native Hawaiian or Other Pacific Islander,

White, or other race/ethnicity group (including Asian Indian, Filipino, ≥2 races/ethnicities, other specified race/ethnicity group, refused to state, or unknown race/ethnicity) (see Supplemental Table 2 for additional race/ethnicity coding). Information on prenatal care engagement was also derived from birth certificate records and included trimester of entry into care (first, second, third, or no care), number of prenatal visits (categorized as 0–4, 5–9, or ≥10), and enrollment in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) [192].

Outcome Measures

The primary outcome was PTB, defined as delivery before 37 completed weeks of gestation, based on the best obstetric estimate recorded on the birth certificate. This estimate typically integrates clinical information such as last menstrual period (LMP), early ultrasound findings, and other relevant data [193]. PTBs were further categorized as spontaneous, medically-indicated, or of unknown subtype. Births documented as having "preterm premature rupture of membranes" (PPROM), "preterm labor," or accompanied by evidence of tocolytic administration were classified as spontaneous PTB. PTBs that were not spontaneous with documentation of "medical induction," "assisted rupture of membranes," or cesarean delivery prior to 37 weeks were considered medically-indicated. Individuals with PTB that lacked codes for either spontaneous or medically-indicated categories were classified as unknown subtype (see Supplemental Table 2 for coding).

Predictor-PTB relationships were evaluated in comparison to individuals who had term birth (≥37 weeks) without "other adverse pregnancy outcomes," defined in this study as birth at ≥37 weeks with one or more of the following: early term birth (37–38 weeks), LBW, small-for-gestational-age birth (SGA; birth weight <10th percentile for gestational age and sex [195]), preeclampsia, "other placental problems" (placenta previa, placental abruption, or placental accreta), SMM [194], major structural congenital anomaly in the infant, maternal death (within 1 year postpartum), or infant death (within 1 year). Additional coding details are provided in Supplemental Table 2.

Statistical Analysis

Descriptive statistics were generated for both training and testing samples, including distributions of maternal characteristics (age, parity, race/ethnicity, insurance type, education) and rates of PTB. In the training sample, Poisson regression was used to assess the association between each actionable risk factor and PTB. Relative risks (RRs), 95% confidence intervals (CIs), and beta coefficients were reported.

Individual PTB-ARIx scores were computed for use during pregnancy at <20-week and ≥20-week gestation by summing the beta coefficients of risk factors present for each individual in both the training and testing samples. The hospital discharge record did not specify the timing of most risk factors. Therefore, all factors were included in both the <20-week and ≥20-week models, except for diagnoses where timing is specific to the diagnoses (e.g., chronic vs. gestational hypertension, preexisting vs. gestational diabetes). As such, gestational hypertension and gestational diabetes were included only in the ≥20-week model. Additional beta-weighted points were assigned for individuals with more than one high-risk or more than two moderate-risk factors for preeclampsia, based on observed effects from regression models.

The association between per-unit increases in PTB-ARIx score and risk of PTB (vs. term birth without adverse outcome) was evaluated using Poisson regression, with associated RRs and 95% CIs reported. Predictive performance was assessed using receiver operating characteristic (ROC) curves and area under the curve (AUC) metrics. Analyses were stratified by timing of PTB (<32, 32–36 weeks), by PTB subtype (spontaneous vs. medically-indicated), and by co-occurring preeclampsia. PTB-ARIx associations were also examined within race/ethnicity and insurance subgroups. Additional analyses assessed the predictive capacity of PTB-ARIx scores for identifying individuals with other adverse outcomes occurring without PTB.

To examine potential gradients in risk, rates of PTB and other adverse outcomes were compared across PTB-ARIx (<20-week and ≥20-week) score categories: 0.0, >0.0–<1.0, 1.0–<2.0, 2.0–<3.0, and ≥3.0 (based on adding beta coefficients for risk factors present). Poisson regression was used to estimate the risk of PTB or other adverse outcomes compared to term births without complications, with each score group (>0.0) compared to the reference group (score = 0.0).

Although treatment-specific variables were not available, we examined potential mediation by measuring the change in RR in unadjusted versus adjusted Poisson regression models when timing of entry into care (coded 0–3: none, third, second, or first trimester based on level of expected protection) and number of prenatal visits (grouped as <3, 3–6, 7–10, >10; coded 1–4) were included in models examining the relationship between PTB-ARIx score by category (0.0, >0.0–<1.0, 1.0–<2.0, 2.0–<3.0, ≥3.0 vs. 0.0) and PTB. Percentage of potential mediation was calculated as: [RR_unadjusted – RR_adjusted] / [RR_unadjusted – 1] × 100, with 95% CIs obtained using the delta method, based on model-derived variances [196].

All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC). The study received ethical approval from the Committee for the Protection of Human Subjects, California Health and Human Services Agency. The study adhered to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines [197].

**Results**

Sample Characteristics

In both the training and testing samples, most individuals giving birth were between 18 and 34 years of age (75.9% and 74.2%, respectively), were multiparous (61.5% and 60.6%), and had more than 12 years of education (57.7% and 58.2%). Nearly half identified as Hispanic (47.5% and 47.8%), and over 40% had public insurance (43.5% and 41.5%). The prevalence of PTB was 7.0% in the training sample and 7.2% in the testing sample. More than one-third of individuals in both samples had term deliveries complicated by one or more adverse pregnancy outcomes (34.3% and 35.4%) (Table 2). The most frequent adverse outcomes in those without PTB were early term birth (37–38 weeks; 71.6% and 72.3%) and SGA birth (23.5% and 22.4%) (Supplemental Table 3).

Candidate Actionable Risk Factors

All candidate actionable risk factors identified for inclusion in the study (Table 1) were associated with an increased risk of PTB in the training sample. Composite preeclampsia-related factors demonstrated the strongest associations. The highest risk observed was in individuals with ≥1 high-risk factor and ≥2 moderate-risk factors for preeclampsia, which occurred in 8.5% of those with PTB compared to 1.4% of those with term birth and no other adverse pregnancy outcome (RR 6.73, 95% CI 6.57, 6.89). The presence of ≥1 high-risk factor without ≥2 moderate-risk factors was also associated with substantial elevation in risk (3.1% vs. 1.0%; RR 4.52, 95% CI 4.35, 4.69). Having ≥2 moderate-risk factors without any high-risk factors conferred a more modest increase in risk (RR 1.91, 95% CI 1.88, 1.94); however, nearly half of PTB cases (49.0% vs. 43.9%) fell into this group. Importantly, each additional high-risk factor for preeclampsia beyond one was associated with nearly a threefold increase in risk (RR 2.88, 95% CI 2.84, 2.92), and each additional moderate-risk factor above two conferred a 35% increase in risk (RR 1.35, 95% CI 1.34, 1.36) (Table 3).

Several additional risk factors were associated with threefold or greater increases in PTB risk. Both prior PTB and gestational hypertension were associated with a fourfold increase in risk (4.0% vs. 0.6%, RR 4.26, 95% CI 4.13, 4.39; and 15.4% vs. 3.0%, RR 4.26, 95% CI 4.13, 4.39, respectively). Although less prevalent, sickle cell anemia, cancer or

malignancy, and homelessness or housing insecurity were each associated with more than a threefold increase in risk (Table 3).

While several other risk factors were associated with more moderate elevations in risk (RRs ranging from 1.29 to 1.85, all 95% CIs >1.0), many were relatively common, occurring in more than 10% of premature births. These included gestational diabetes (13.6%), anemia (13.2%), non-STI infections (16.7%), and having one or more mental health conditions (14.6%) (Table 3).

Cumulative Risk and the PTB-ARIx Score: Patterns and Prediction

More than two-thirds of individuals in the study had at least one actionable risk factor (67.2% and 69.4% in the training and testing samples, respectively; ranges 0–12 and 0–10). Over one-quarter had two or more risk factors (28.1% and 29.4%). The mean number of risk factors present was 1.60 (SD 1.35) for individuals with a PTB, 1.25 (1.18) for individuals with a term birth with another adverse outcome, and 0.97 (0.99) for term births without adverse outcomes in the training sample, and 1.59 (1.37), 1.33 (1.21), and 1.00 (1.00) in the testing sample (Supplemental Table 4).

Each unit increase in the <20-week PTB-ARIx score (calculated as the sum of beta coefficients for each risk factor present, with additional points for >1 high-risk or >2 moderate-risk factors for preeclampsia as described in Methods) was associated with a >60% increased risk of PTB in the training sample (RR 1.67, 95% CI 1.67, 1.68) (Table 4). This association was consistent across insurance-by-race/ethnicity groups, with per-unit risk estimates exceeding 1.60 in nearly all strata. Exceptions included American Indian/Alaska Native, Black, Other race/ethnicity, and ≥2 races/ethnicities with public insurance, where per-unit risks ranged from 1.47 to 1.53 (all CIs >1.0) (Supplemental Table 5).

Findings with respect to the association between per-unit increase in the <20-week PTB-ARIx score and PTB were similar in the testing sample (RR 1.66, 95% CI 1.64, 1.68) and were also found to be similar with respect to ≥20-week PTB-ARIx score findings. Specifically, each per-unit increase in the ≥20-week PTB-ARIx score was associated with >60% increase in risk for PTB in both the training (RR 1.72, 95% CI 1.71, 1.72) and testing (RR 1.67, 95% CI 1.66, 1.69) samples. Importantly, per-unit increases in both <20- and ≥20-week scores were associated with early (<32 weeks) and late PTB (32–36 weeks), as well as with spontaneous and medically-indicated PTB, and with co-occurring preeclampsia (Table 4). Stronger associations were observed for early PTB, wherein per-unit increases in the <20-week score were associated with more than a twofold increase in PTB risk in both the training and testing samples (RR 2.17, 95% CI 2.14, 2.19; RR

2.08, 95% CI 2.03, 2.13, respectively). The relationship was particularly pronounced for early PTB with preeclampsia, wherein per-unit increases in the <20-week score were associated with nearly a threefold increase in risk (RR 2.91, 95% CI 2.85, 2.97; RR 2.91, 95% CI 2.79, 3.02) and per-unit increases in the ≥20-week score were associated with more than a threefold increase in risk in both the training and testing samples (RR 3.27, 95% CI 3.21, 3.32; RR 3.27, 95% CI 3.16, 3.39).

Performance of the <20- and ≥20-week PTB-ARIx scores by AUC indicated stronger discrimination for PTB <32 weeks. The prediction was particularly robust when PTB <32 weeks co-occurred with preeclampsia. The <20-week PTB-ARIx score showed modest discrimination for late PTB (AUC 0.626, 95% CI 0.625, 0.628, and AUC 0.628, 95% CI 0.623, 0.632 in the training and testing samples, respectively). Performance improved for PTB <32 weeks, with AUCs of 0.691 (95% CI 0.686, 0.696) and 0.676 (95% CI 0.666, 0.686), respectively. Discrimination exceeded 70% for spontaneous and medically-indicated PTB <32 weeks and surpassed 80% when PTB <32 weeks co-occurred with preeclampsia (Supplemental Table 7, Figure 1).

The ≥20-week PTB-ARIx score demonstrated stronger performance across outcomes compared to the <20-week score. For spontaneous PTB <32 weeks in the training sample, the AUC was 0.745 (95% CI 0.737, 0.753); for medically-indicated PTB <32 weeks, the AUC was 0.880 (95% CI 0.872, 0.889); and for PTB <32 weeks co-occurring with preeclampsia, the AUC reached 0.965 (95% CI 0.963, 0.966), with similar patterns observed in the testing sample (Supplemental Table 7, Figure 1).

<u>Risk Groupings and Mediation Analyses</u>

When the associations between the <20- and ≥20-week PTB-ARIx scores, PTB, and term birth accompanied by another adverse pregnancy outcome were examined by risk score groupings (0.01–<1.00, 1.00–<2.00, 2.00–<3.00, ≥3.00) compared with the 0.00 reference group, consistent gradients of increasing risk were observed. For the <20-week PTB-ARIx score, 4.7% of individuals with a score of 0.00 in the training sample experienced PTB, compared with 6.4%, 9.8%, 16.7%, and 26.1% in the 0.01–<1.00, 1.00–<2.00, 2.00–<3.00, and ≥3.00 groups, respectively. RRs rose from 1.41 (95% CI 1.39, 1.43) in the 0.01–<1.00 group to 7.04 (95% CI 6.85, 7.24) in the ≥3.00 group. Similar patterns were observed in the testing sample, with PTB rates ranging from 6.4% to 26.6% among those with scores >0.00 compared with 5.0% in the 0.00 group (RRs 1.32 to 6.99; all 95% CIs >1.00). Associations between <20-week PTB-ARIx groupings and term birth with another adverse outcome were more modest but demonstrated the same pattern. In the training

sample, 31.9% of those with a score of 0.00 experienced a term birth with an adverse outcome compared with 46.4% in the ≥3.00 group (RR 1.88, 95% CI 1.84, 1.91), with similar findings seen in the testing sample (Figure 2; Supplemental Table 8).

In the training sample, 4.3% of individuals with a ≥20-week PTB-ARIx score of 0.00 had a PTB, whereas rates rose to 5.7%, 8.8%, 14.7%, and 23.9% across the 0.01–<1.00, 1.00–<2.00, 2.00–<3.00, and ≥3.00 groups, respectively. Corresponding RRs ranged from 1.36 (95% CI 1.34, 1.38) in the 0.01–<1.00 group to 8.04 (95% CI 7.85, 8.23) in the ≥3.00 group. In the testing sample, PTB rates increased from 4.8% in the 0.00 group to 5.9%–23.2% across higher groupings, with RRs of 1.26 to 7.47 (all 95% CIs >1.00). For term births complicated by another adverse outcome, risk patterns were more modest but still graded. In the training sample, 30.1% of those with a score of 0.00 experienced a term birth with an adverse outcome, compared with 51.5% in the ≥3.00 group (RR 2.15, 95% CI 2.12, 2.18). A similar gradient was evident in the testing sample (Figures 2–3; Supplemental Table 8).

Adjusting models for timing of entry into care (coded 0–3, where 0 = no prenatal care and 1–3 = third, second, and first trimesters, respectively) did not change the observed associations between <20- and ≥20-week PTB-ARIx scores and PTB in either training or testing subsets (with percentage possibly mediated values ranging from 0.00 to 4.67%, and all lower bounds of the 95% CIs <0.00). In contrast, including number of prenatal visits (coded 1–4, corresponding to <3, 3–6, 7–10, and 11+ visits) demonstrated robust associations, particularly for the ≥3.00 versus 0.00 PTB-ARIx score comparisons. For example, in the <20-week PTB-ARIx model for PTB in the training sample, the RR decreased from 7.04 (95% CI 6.85, 7.24) to 5.11 (95% CI 4.96, 5.26), corresponding to 31.95% possibly mediated (95% CI 28.64%, 35.27%). In the ≥20-week PTB-ARIx model, the RR decreased from 8.04 (95% CI 7.85, 8.23) to 6.38 (95% CI 6.22, 6.53), with 23.58% possibly mediated (95% CI 20.56%, 26.60%) (Figure 4; Supplemental Table 9). Similar patterns were observed in the testing sample (Figure 4; Supplemental Table 9).

**Discussion**

In this large, population-based study, we developed and tested the PTB-ARIx, a tool designed to identify pregnant individuals at increased risk for PTB based on actionable risk factors observed before and after 20 weeks' gestation. In this context, the PTB-ARIx demonstrated consistent associations with PTB overall and across subtypes, with the strongest predictive power observed for early PTB and for early PTB co-occurring with preeclampsia. Notably, we found that each unit increase in the <20-week and ≥20-week PTB-ARIx scores was associated with more than a 60% elevation

in PTB risk, wherein effect sizes were found to increase as gestational age at delivery decreased and when PTB co-occurred with preeclampsia. For early PTB, per-unit increases in the <20-week score conferred more than a twofold increase in risk, and risks approached threefold for early PTB complicated by preeclampsia. Discrimination was modest for late PTB but improved substantially for early PTB, surpassing 0.70 for both spontaneous and medically-indicated subtypes, and exceeding 0.80 when early PTB occurred with preeclampsia. The ≥20-week PTB-ARIx score achieved potent discrimination for early PTB co-occurring with preeclampsia, with AUC values approaching 0.97.

Importantly, when PTB-ARIx scores were stratified by score levels, some groups were found to be at especially increased risk for PTB or for term birth occurring with other adverse outcomes. About three in four of those with a <20- or ≥20-week PTB-ARIx score of ≥3.00 had a PTB or term birth with another adverse outcome in both the training and testing samples. While data were not available on whether individuals received any treatment or intervention related to specific risk factors, when the number of prenatal visits was evaluated as a proxy, findings revealed potentially potent mediation of risk as a function of receipt of care, especially in those with scores at or above 3.00 (with percentage possibly mediated values ranging from about 20% for <20-week PTB-ARIx score and PTB in the testing sample to about 32% for ≥20-week PTB-ARIx score and PTB in the training sample).

Risk Prediction: PTB-ARIx Compared to Other Metrics

Findings from the present study are consistent with prior investigations in terms of observed associations between specific risk factors and PTB [2,3,34,35,173,177,198]. However, notable differences emerge when comparing this work with other prediction efforts that have relied on clinical, social, and behavioral factors, in terms of factors included in models and in performance, particularly by timing of PTB, subtype, and co-occurrence with preeclampsia [173,175–177,199,200]. Across studies focused on prediction using only clinical and social factors, without additional biomarker testing such as blood pressure, cervical length, or metabolite or cytokine assays, reported AUCs have generally fallen between 0.6 and 0.7 for second-trimester or earlier prediction [173,175-177], with somewhat higher values observed for prediction later in pregnancy [173,176].

Importantly, many prior PTB prediction efforts have relied on nonmodifiable and structurally mediated patient factors (e.g., parity, race/ethnicity, poverty) [173,175-177]. In contrast, our model centers on factors embedded within transparent, existing, actionable interventions prescribed by providers, such as USPSTF recommendations for aspirin prophylaxis [38]. This aligns with priorities identified by both patients and providers for improving risk assessment and

communication [167-172]. This framing allows the grouping of certain factors into composites, thereby distinguishing this work from prior models and supporting clearer opportunities for translation into care.

Another key distinction of this study is the evaluation of model performance across PTB subtypes, including early and late PTB, spontaneous and medically-indicated PTB, and PTB co-occurring with preeclampsia, reported in the full study cohort. Prior work has often focused narrowly on spontaneous PTB or PTB with preeclampsia, limiting generalizability. For example, a 2024 review by van Eekhout et al. reported a pooled AUC of 0.61 (95% CI 0.60, 0.64) for first-trimester models of spontaneous PTB using maternal characteristics [201]. By comparison, the <20-week PTB-ARIx score showed stronger performance for spontaneous PTB (AUCs 0.648 and 0.661 in training and testing) and even higher accuracy for spontaneous PTB at <32 weeks (0.712 and 0.717). The same model also demonstrated high predictive value for medically-indicated PTB (AUCs 0.680–0.796) and for PTB with preeclampsia (0.771–0.827), underscoring the importance of evaluating performance across phenotypes.

With respect to the added contribution of biomarkers, prior studies incorporating measures such as cervical length and cytokines (e.g., IL-6 and TNF-α) have consistently reported AUCs exceeding 0.75 for prediction of spontaneous PTB [174]. This pattern of improvement with biomarker integration has also been observed for broader PTB prediction by our group and others [186,202,203]. While the PTB-ARIx is notable for achieving actionable prediction without additional testing, these findings highlight the potential for even greater accuracy when combined with biomarker data, particularly when used to address known gaps in translation to practice. For example, aspirin prophylaxis in women at elevated risk for preeclampsia [204] and the use of psychotropic medications in women with depression [205] have been shown to reduce the levels of inflammation-related biomarkers (e.g., CRP, TNF-α). A deeper understanding of whether and how treatment influences biomarker signaling and PTB risk could yield important insights into mechanisms of intervention impact. Because the PTB-ARIx is based entirely on actionable risk factors, it may serve as a useful framework for comparing biomarker patterns in high-risk individuals who are pregnant with and without treatment.

Of particular importance, the <20-week PTB-ARIx achieved AUCs >0.80 for early PTB with preeclampsia in both training and testing samples, while the ≥20-week PTB-ARIx achieved AUCs >0.95 for both early and late PTB with preeclampsia. These findings align with prior studies demonstrating strong first- and second-trimester prediction of PTB with preeclampsia using clinical and social factors, considered with and without additional biomarkers [206,207]. As mentioned previously, however, the distinguishing feature of the PTB-ARIx is its exclusive focus on actionable risk.

Specifically, for PTB with preeclampsia, the model incorporates composite groups defined by the presence of one or more high-risk factors and/or two or more moderate-risk factors for preeclampsia (consistent with USPSTF recommendations [38]). Within this frame, the PTB-ARIx also accounts for and leverages how risk accumulates when multiple factors are present. To our knowledge, no other model has applied this approach to prediction or risk stratification for PTB with preeclampsia, despite substantial evidence that risk increases when clinical and social factors co-occur [208,209]. Notably, a recent study employed USPSTF guidelines to examine the relationship between high- and moderate-risk factors and the occurrence of preeclampsia with and without aspirin use [210], but investigators did not evaluate patterns of risk when these factors co-occurred, nor did they assess whether or how risk accumulates when risk factors co-occur. Findings from the present study suggest that models seeking to identify individuals at increased risk for preeclampsia would be strengthened by a more robust incorporation of risk co-occurrence and accumulation.

Risk Stratification and Actionable Inroads for Intervention

Findings from the present study demonstrate that risk for PTB overall, and by timing, subtype, and co-occurrence with preeclampsia increases substantially as <20- and ≥20-week PTB-ARIx scores increase. Given that the indices rely exclusively on actionable risk factors, all score groupings above 0.00 point to the need for action and follow-up. This framing distinguishes the PTB-ARIx from many other PTB prediction efforts that often emphasize cut points or thresholds at which action should be initiated [176,211,212]. By focusing on actionable risk, the PTB-ARIx highlights opportunities to ensure that clinical, social, or behavioral factors linked to elevated risk, and for which evidence-based interventions exist, can be translated into tailored care. This framing redirects focus from a threshold-for-action design to one that ensures that all interventions are implemented equitably and in accordance with patient preferences. Such an approach creates opportunities to strengthen alignment with ACOG and SMFM recommendations to adopt care models that integrate medical complexity, psychosocial context, and patient values [179-181].

Because the PTB-ARIx is anchored in actionable risk, its application extends across all risks and risk groupings, whether an individual has one or multiple factors present. For example, while factors such as anemia, asthma, and STIs were associated with more modest elevations in risk (RRs 1.25–1.40), each is linked to well-established interventions that improve maternal health and have been shown to be associated with a reduction in risk for PTB and/or risk for other adverse pregnancy outcomes when used (e.g., oral iron therapy or transfusion for anemia [76], inhaled corticosteroids for asthma [72], screening and treatment for STIs [89,90]) [74,77,91,92]. Thus, the PTB-ARIx emphasizes

not only transparent risk assessment but also the translation of risk into uptake of interventions, creating a pathway to closing care gaps.

Of particular importance in considering the PTB-ARIx is the recognition that **care milieu** profoundly shapes whether risk is communicated, whether interventions are recommended, and ultimately, whether they are adopted. Breakdowns in this feedback loop are starkly exemplified in patterns of recommendation and uptake of aspirin in pregnancy. Despite robust evidence from randomized trials and guideline endorsements, many patients who would benefit from aspirin use are never counseled about it, and many do not initiate use once prescribed [40]. Moreover, pronounced inequities in both prescription and uptake have been documented [41,210]. These patterns underscore the importance of evaluating the PTB-ARIx through a lens that considers not only predictive accuracy but also its potential role in supporting equitable care delivery and reducing disparities in intervention uptake more broadly.

Beyond enhancing knowledge of risk factors and related interventions, the PTB-ARIx has the potential to strengthen understanding of PTB and its early warning signs, thereby supporting sustained engagement with prenatal care and encouraging earlier care-seeking when symptoms arise. Prior work demonstrates that many individuals first learn about treatments such as tocolytics (to delay labor), magnesium sulfate (to protect neurodevelopment), and antenatal corticosteroids (to accelerate fetal lung development) [213] only in emergency settings, contributing to fear, limited preparedness, and challenges in decision-making [214,215]. In contrast, earlier and proactive communication about PTB risk during routine care has been shown to improve preparedness, build trust, and increase acceptance of evidence-based interventions [214-216]. Embedding the PTB-ARIx into prenatal care pathways may therefore not only increase understanding and uptake of interventions linked to specific risk factors and conditions, but also the broader awareness of PTB and its early signs, facilitating timelier initiation of proven therapies that can improve maternal and neonatal outcomes if premature labor occurs.

Strengths and Limitations

This study has several notable strengths. The use of a large, population-based dataset enabled robust evaluation of PTB risk across subgroups defined by timing, subtype, and co-occurrence with preeclampsia. By centering the PTB-ARIx on actionable risk factors, the study advances a pragmatic framework that directly connects prediction to opportunities for intervention, aligning with professional calls to incorporate medical complexity, psychosocial context, and patient preferences into prenatal care [179-181]. A key methodological strength was our reliance on crude rather than adjusted

risks when deriving risk scores. Adjustment of individual factors in risk models can lead to over-adjustment bias, obscuring the true impact of correlated and cumulative exposures on outcomes [217,218]. By using crude risks and their related beta coefficients, the PTB-ARIx better reflects the aggregate contribution of co-occurring actionable factors, thereby capturing the cumulative burden of medical, social, and behavioral risks. This approach reduces the likelihood of underestimating risk associated with multiple intersecting exposures, a limitation inherent in scores based on adjusted associations. Study design also permitted novel analyses of PTB risk in relation to term births complicated by other adverse outcomes. While these findings will require robust follow-up and investigation in and of themselves, they represent findings rarely considered in prior work. Furthermore, the PTB-ARIx demonstrated robustness across insurance types and race/ethnicity groups, supporting the potential for broad generalizability and the opportunity to inform strategies for addressing inequities in adverse pregnancy outcomes.

Several limitations should also be acknowledged. The use of a large administrative database, while enabling population-level analyses, limited the ability to capture detailed clinical and treatment-related information. Measures such as timing of entry into care and number of prenatal visits served only as proxies for the quality and content of care and did not reflect treatment initiation, adherence, or clinical management. This constrains inference about the mechanisms through which actionable risks may be modified. Also critical is that this administrative dataset did not include information about timing of diagnoses and, as such, some factors like infection may have occurred earlier or later in pregnancy and instead were included in both sets of models. Moving forward, it will be critical to examine model performance by timing of exposures. Also of critical importance is the lack of information about the severity of conditions like diabetes and blood pressure. This will be a very important area of investigation moving forward, as what constitutes "actionable risk" in these groups is strongly tied to severity [38,42,45,46,63,64,68].

Although the PTB-ARIx demonstrated consistent performance across diverse subgroups, prospective validation in specific populations and health system settings is needed to confirm generalizability and guide integration into prenatal care. A further limitation is our limited evaluation of individuals with term deliveries complicated by other adverse outcomes (e.g., early term birth, SGA, SMM). In this study, these outcomes were grouped under a single umbrella given their established short- and long-term associations with maternal and infant morbidity [219-227]. However, the relationship between cumulative risk and each outcome remains unclear. While substantial data link individual risk factors (e.g., maternal hypertension, diabetes, SDoH) to these outcomes [228-231], associations with cumulative risk

have not been examined in depth. Future work should assess whether the PTB-ARIx can be adapted to improve prediction and uptake of evidence-based interventions related to other target outcomes, or determine whether adaptation of other models or the development of new outcome-specific actionable indexes is warranted [232,233].

Next Steps

Given persistent inequities in the occurrence of PTB and related risks [3,33-35], building on these findings, next steps should prioritize external validation of the PTB-ARIx across racially/ethnically and sociodemographically diverse populations, with particular attention given to prospective cohorts that allow for more precise evaluation of care processes and quality as well as timing of exposures. Complementary qualitative work with patients and providers will be essential to identify and understand know-do gaps, optimize communication of risk, and ensure interventions are delivered in preference-concordant ways to allow improved uptake by the patients that need them the most.

Evaluation of the PTB-ARIx as a patient-facing tool in clinical or community settings will also be critical to determine its acceptability, feasibility, and potential to improve understanding of risk and uptake of evidence-based interventions. In parallel, integration of PTB-ARIx-defined risk with biomolecular measures offers opportunities both to improve prediction through multimodal models and to uncover mechanistic pathways underlying PTB and related complications.

More broadly, extending the actionable risk framework beyond PTB to other maternal and infant outcomes, including those encompassed in the "term other adverse outcomes" grouping, should be prioritized. Notably, this includes SMM and maternal mortality, where predictive models may similarly benefit from an increased focus on risk factors that are both routinely measured and modifiable [232,233].

**Conclusions**

This study introduces the PTB-ARIx as a novel approach for assessing risk for PTB and related adverse outcomes by centering on actionable risk factors, namely those with known evidence-based interventions that can be initiated during pregnancy. By shifting the focus from prediction alone to risk domains where treatment and support may reduce adverse outcomes, the PTB-ARIx highlights an important opportunity to align risk assessment with action. Findings demonstrate robust performance across subgroups and point to the potential for PTB-ARIx to advance more equitable, patient-centered models of prenatal care. Prospective validation will be essential to confirm its clinical utility. At the practice level, the PTB-ARIx may help guide timely identification and intervention, while at the policy level, its emphasis

on actionable risk underscores the need to embed medical, structural, social, and behavioral determinants into standard

frameworks for maternal health equity and resource allocation.

**References**

1. Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet. 2023;402(10409):1261–71. doi:10.1016/S0140–6736(23)00878-4

2. Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Preterm birth: causes, consequences, and prevention. Behrman RE, Butler AS, editors. Washington (DC): National Academies Press (US);2007. pmid:20669423

3. Centers for Disease Control and Prevention, National Center for Health Statistics. National vital statistics system, Weeks Gestation (by insurance, race/ethnicity, and state). Data are from the Natality Records 2016–23, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http: //wonder.cdc.gov/natality-expanded-current.html. (accessed 2025 Sep 28).

4. Waitzman NJ, Jalali A, Grosse SD. Preterm birth lifetime costs in the united states in 2016: an update. Semin Perinatol. 2021;45(3):151390. doi:10.1016/j.semperi.2021.151390 pmid:33541716

5. Moon G, English M and Nagraj S. A landscape analysis of the key global stakeholders working on interventions around preterm birth that improve neonatal mortality and morbidity. Wellcome Open Res 2024, 8:220. doi.org/10.12688/wellcomeopenres.19000.2)

6. DeNoble AE, Heine RP, Dotters-Katz SK. Chorioamnionitis and infectious complications after vaginal delivery. Am J Perinatol. 2019;36(14):1437–41. doi:10.1055/s-0039–1692718 pmid:31238347

7. Lyndon A, Baer RJ, Gay CL, El Ayadi AM, Lee HC, Jelliffe-Pawlowski L. A population-based study to identify the prevalence and correlates of the dual burden of severe maternal morbidity and preterm birth in california. J Matern Fetal Neonatal Med. 2021;34(8):1198–206. doi:10.1080/14767058.2019.1628941 pmid:31170837

8. Garland CE, Geller SE, Koch AR. Adverse delivery and neonatal outcomes among women with severe maternal morbidity in illinois, 2018–9. J Womens Health (Larchmt). 2024;33(2):163–70. doi:10.1089/jwh.2023.0248 pmid:37972060

9. Amar S, Potter BJ, Paradis G, Lewin A, Maniraho A, Brousseau É, et al. Outcomes of postpartum preeclampsia: a retrospective cohort study of 1.3 million pregnancies. BJOG. 2024 Dec 2. doi:10.1111/1471–0528.18030 pmid: 39623781

10. McNestry C, Killeen SL, Crowley RK, McAuliffe FM. Pregnancy complications and later life women's health. Acta Obstet Gynecol Scand. 2023;102(5):523–31. doi:10.1111/aogs.14523 pmid:36799269

11. Barrett PM, McCarthy FP, Kublickiene K, Cormican S, Judge C, Evans M, et al. Adverse pregnancy outcomes and long-term maternal kidney disease: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(2): e1920964. doi:10.1001/jamanetworkopen.2019.20964 pmid:32049292

12. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation. 2019;139(8):1069–79. doi:10.1161/CIRCULATIONAHA.118.036748

13. Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O'Brien S, et al. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7(2): e007809. doi:10.1161/JAHA.117.007809 pmid:29335319

14. Crump C. An overview of adult health outcomes after preterm birth. Early Hum Dev. 2020;150:105187. doi:10.1016/j.earlhumdev.2020.105187 pmid:32948365

15. Raju TNK, Buist AS, Blaisdell CJ, Moxey-Mims M, Saigal S. Adults born preterm: a review of general health and system-specific outcomes. Acta Paediatr. 2017;106(9):1409–37. doi:10.1111/apa.13880 pmid:28419544

16. Crump C, Sundquist J, Sundquist K. Preterm delivery and long term mortality in women: national cohort and co-sibling study. BMJ. 2020;370: m2533. doi:10.1136/bmj.m2533 pmid:32816755

17. Crump C, Sundquist J, Sundquist K. Adverse pregnancy outcomes and long-term mortality in women. JAMA Intern Med. 2024;184(6):631–40. doi:10.1001/jamainternmed.2024.0276 pmid:38619848

18. Ahmed AM, Grandi SM, Pullenayegum E, McDonald SD, Beltempo M, Premji SS, et al. Short-term and long-term mortality risk after preterm birth. JAMA Netw Open. 2024;7(11): e2445871. doi:10.1001/jamanetworkopen.2024.45871 pmid:39565625

19. Venkatesan T, Rees P, Gardiner J, Battersby C, Purkayastha M, Gale C, et al. National trends in preterm infant mortality in the united states by race and socioeconomic status, 1995–2020. JAMA Pediatr. 2023;177(10):1085–95. doi:10.1001/jamapediatrics.2023.3487 pmid:37669025

20. Johnson S, Marlow N. Early and long-term outcome of infants born extremely preterm. Arch Dis Child. 2017;102(1):97–102. doi:10.1136/archdischild-2015–309581 pmid:27512082

21. Morniroli D, Tiraferri V, Maiocco G, De Rose DU, Cresi F, Coscia A, et al. Beyond survival: the lasting effects of premature birth. Front Pediatr. 2023;11:1213243. doi:10.3389/fped.2023.1213243 pmid:37484764

22. Chehade H, Simeoni U, Guignard JP, Boubred F. Preterm birth: long term cardiovascular and renal consequences. Curr Pediatr Rev. 2018;14(4):219–26. doi:10.2174/1573396314666180813121652 pmid:30101715

23. Crump C, Sundquist J, Sundquist K. Stroke risks in adult survivors of preterm birth: national cohort and cosibling study. Stroke. 2021;52(8):2609–17. doi:10.1161/STROKEAHA.120.033797 pmid:34134503

24. Crump C, Sundquist J, Sundquist K. Preterm or early term birth and long-term risk of asthma into midadulthood: a national cohort and cosibling study. Thorax. 2023;78(7):653–60. doi:10.1136/thorax-2022–18931 pmid:35907641

25. Crump C, Sundquist J, Sundquist K. Preterm birth and risk of type 1 and type 2 diabetes: a national cohort study. Diabetologia. 2020;63(3):508–18. doi:10.1007/s00125–019-05044-z pmid:31802143

26. Taine M, Charles MA, Beltrand J, Rozé JC, Léger J, Botton J, et al. Early postnatal growth and neurodevelopment in children born moderately preterm or small for gestational age at term: a systematic review. Paediatr Perinat Epidemiol. 2018;32(3):268–80. doi:10.1111/ppe.12468 pmid:29691880

27. Steurer MA, Ryckman KK, Baer RJ, Costello J, Chambers CD, Jelliffe-Pawlowski LL, McCulloch CE, Oltman SP, Rogers EE. Developing a resiliency model for survival without major morbidity in preterm infants. J Perinatol. 2023;43:452-457. doi:10.1038/s41372-022-01521-3. pmid:36510255

28. Morniroli D, Tiraferri V, Maiocco G, De Rose DU, Cresi F, Coscia A, Mosca F, Giannì ML. Beyond survival: the lasting effects of premature birth. Front Pediatr. 2023;11:1213243. doi:10.3389/fped.2023.1213243 pmid:37484764

29. Hee Chung E, Chou J, Brown KA. Neurodevelopmental outcomes of preterm infants: a recent literature review. Transl Pediatr. 2020;9(Suppl 1): S3-S8. doi:10.21037/tp.2019.09.10 pmid:32206579

30. Pascal A, Govaert P, Oostra A, Naulaers G, Ortibus E, Van den Broeck C. Neurodevelopmental outcome in very preterm and very-low-birthweight infants born over the past decade: a meta-analytic review. Dev Med Child Neurol. 2018;60(4):342–55. doi:10.1111/dmcn.13675 pmid:29350401

31. Rahalkar N, Holman-Vittone A, Daniele C, Wacks R, Gagnon A, D'Agata A, et al. Preterm birth, birthweight, and subsequent risk for depression. J Dev Orig Health Dis. 2023;14(5):623–30. doi:10.1017/S2040174423000296 pmid:37886824

32. James SN, Rommel AS, Rijsdijk F, Michelini G, McLoughlin G, Brandeis D, et al. Is association of preterm birth with cognitive-neurophysiological impairments and adhd symptoms consistent with a causal inference or due to familial confounds? psychol med. 2020;50(8):1278–84.

33. National Institutes of Health, Office of Data Standards. Common data elements and social determinants of health. U.S. Department of Health and Human Services. https://datascience.nih.gov/fhir-initiatives/common-data-elements-and-social-determinants-of-health (accessed 2025 Sep 28).

34. Jelliffe-Pawlowski LL, Baer RJ, Oltman S, McKenzie-Sampson S, Afulani P, Amsalu R, et al. Risk and protective factors for preterm birth among racial, ethnic, and socioeconomic groups in california. JAMA Netw Open. 2024;7(9): e2435887. doi:10.1001/jamanetworkopen.2024.35887 pmid:39331393

35. Centers for Disease Control and Prevention, National Center for Health Statistics. National vital statistics system, Gestational Hypertension (by insurance, race/ethnicity, and state). Data are from the Natality Records 2016–23, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http: //wonder.cdc.gov/natality-expanded-current.html (accessed 2025 Sep 28).

36. El Ayadi AM, Baer RJ, Gay C, Lee HC, Obedin-Maliver J, Jelliffe-Pawlowski L, et al. Risk factors for dual burden of severe maternal morbidity and preterm birth by insurance type in california. Matern Child Health J. 2022;26(3):601–13. doi:10.1007/s10995–021-03313-1 pmid:35041142

37. Karvonen KL, Baer RJ, Rogers EE, Steurer MA, Ryckman KK, Feuer SK, et al. Racial and ethnic disparities in outcomes through 1 year of life in infants born prematurely: a population based study in california. J Perinatol. 2021;41(2):220–31. doi:10.1038/s41372–021-00919-9 pmid: 33514879

38. US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: us preventive services task force recommendation statement. JAMA. 2021;326(12):1186–91. doi:10.1001/jama.2021.14781 pmid:34581729

39. Baradwan S, Tawfiq A, Hakeem GF, Alkaff A, Hafedh B, Faden Y, et al. The effects of low-dose aspirin on preterm birth: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2024;309(5):1775–86. doi:10.1007/s00404–024-07373-w pmid:38372754

40. Singh N, Shuman S, Chiofalo J, Cabrera M, Smith A. Missed opportunities in aspirin prescribing for preeclampsia prevention. BMC Pregnancy Childbirth. 2023;23(1):717. doi:10.1186/s12884–023-06039-w pmid:37805449

41. Olson DN, Russell T, Ranzini AC. Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. Am J Obstet Gynecol MFM. 2022;4(5):100663. doi:10.1016/j.ajogmf.2022.100663 pmid:35580761

42. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1): S282-S294. doi:10.2337/dc24-S015 pmid:38078583

43. Sekhon J, Graham D, Mehrotra C, Li I. Continuous glucose monitoring: a cost-effective tool to reduce preterm birth rates in women with type one diabetes. Aust N Z J Obstet Gynaecol. 2023;63(2):146–53. doi:10.1111/ajo.13581 pmid:35833262

44. Venkatesh KK, Powe CE, Buschur E, Wu J, Landon MB, Gabbe S, et al. Disparities in continuous glucose monitoring use among women of reproductive age with type 1 diabetes in the t1d exchange. Diabetes Technol Ther. 2023;25(3):201–5. doi:10.1089/dia.2022.0412 pmid:36753706

45. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Acog practice bulletin no. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019;133(1): e26-e50. doi:10.1097/AOG.0000000000003020 pmid:30575676

46. Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network meta-analysis. Am J Obstet Gynecol. 2020;223(4):525–37. doi:10.1016/j.ajog.2020.03.016 pmid:32199925

47. Richards EMF, Giorgione V, Stevens O, Thilaganathan B. Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023;228(4):395–408. doi:10.1016/j.ajog.2022.09.046 pmid:36209937

48. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Chronic hypertension and pregnancy (chap) trial consortium. Treatment for mild chronic hypertension during pregnancy. N Engl J Med. 2022;386(19):1781–92. doi:10.1056/NEJMoa2201295 pmid:35363951

49. Leonard SA, Siadat S, Main EK, Huybrechts KF, El-Sayed YY, Hlatky MA, et al. Chronic hypertension during pregnancy: prevalence and treatment in the united states, 2008–21. Hypertension. 2024;81(8):1716–23. doi:10.1161/HYPERTENSIONAHA.124.22731 pmid:38881466

50. Fernández-Buhigas I. Obstetric management of the most common autoimmune, diseases: a narrative review. Front Glob Womens Health. 2022;3:1031190. doi:10.3389/fgwh.2022.1031190 pmid:36505012

51. Zhu Q, Wang J, Sun Q, Xie Z, Li R, Yang Z, et al. Effect of hydroxychloroquine on pregnancy outcome in patients with sle: a systematic review and meta-analysis. Lupus Sci Med. 2024;11(2): e001239. doi:10.1136/lupus-2024–001239 pmid:39477333

52. Clowse MEB, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz et al. Hydroxychloroquine in the i of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022;9(1): e000651. doi:10.1136/lupus-2021–000651 pmid:35318256

53. Simard JF, Liu EF, Chakravarty E, Rector A, Cantu M, Kuo DZ, et al. Reconciling between medication orders and medication fills for lupus in pregnancy. ACR Open Rheumatol. 2022;4(12):1021–6. doi:10.1002/acr2.11501 pmid:36252776

54. Reynolds ML, Herrera CA. Chronic kidney disease and pregnancy. Adv Chronic Kidney Dis. 2020;27(6):461–8. doi:10.1053/j.ackd.2020.04.003 pmid:33328062

55. Copur S, Berkkan M, Basile C, Cozzolino M, Kanbay M. Dialysis in pregnancy: an update review. Blood Purif. 2023;52(7-8):686–93. doi:10.1159/000531157 pmid:37379824

56. Piccoli GB, Minelli F, Versino E, Cabiddu G, Attini R, Vigotti FN, et al. Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules

and pregnancy outcomes. Nephrol Dial Transplant. 2016;31(11):1915–34. doi:10.1093/ndt/gfv395 pmid:26614270

57. Wallace EL, Lea J, Chaudhary NS, Griffin R, Hammelman E, Cohen J, et al. Home dialysis utilization among racial and ethnic minorities in the united states at the national, regional, and state level. Perit Dial Int. 2017 1-2;37(1):21–9. doi:10.3747/pdi.2016.00025 pmid:27680759

58. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. Obstet gynecol. 2021;138(2): e65-e90. doi:10.1097/AOG.0000000000004479 pmid:34293771

59. American College of Obstetricians and Gynecologists. Updated guidance: use of progesterone supplementation for prevention of recurrent preterm birth. Practice advisory. 2023 Apr. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/04/updated-guidance-use-of-progesterone-supplementation-for-prevention-of-recurrent-preterm-birth (accessed 2025 Sep 28).

60. Conde-Agudelo A, Romero R, Da Fonseca E, O'Brien JM, Cetingoz E, Creasy GW, et al. Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis. Am J Obstet Gynecol. 2018;219(1):10–25. doi:10.1016/j.ajog.2018.03.028 pmid:29630885

61. Aubin AM, McAuliffe L, Williams K, Issah A, Diacci R, McAuliffe JE, Sabdia S, Phung J, Wang CA, Pennell CE. Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(8):101024. doi:10.1016/j.ajogmf.2023.101024 pmid:37211087

62. Luxenbourg D, Porat S, Romero R, Raif Nesher D, Haj Yahya R, Sompolinsky Y, et al. The effectiveness of vaginal progesterone in reducing preterm birth in high-risk patients diagnosed with short cervical length after 24 weeks: a retrospective cohort study. Front Med (Lausanne). 2023;10:1130942. doi:10.3389/fmed.2023.1130942 pmid:36936220

63. ACOG Practice Bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2): e49-e64. doi:10.1097/AOG.0000000000002501 pmid:29370047

64. Martis R, Crowther CA, Shepherd E, Alsweiler J, Downie MR, Brown J. Treatments for women with gestational diabetes mellitus: an overview of cochrane systematic reviews. Cochrane Database Syst Rev. 2018;8(8): CD012327. doi:10.1002/14651858.CD012327.pub2 pmid:30103263

65. Behboudi-Gandevani S, Bidhendi-Yarandi R, Panahi MH, Vaismoradi M. The effect of mild gestational diabetes mellitus treatment on adverse pregnancy outcomes: a systemic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:640004. doi:10.3389/fendo.2021.640004 pmid:33841332

66. Venkatesh KK, Chiang CW, Castillo WC, Battarbee AN, Donneyong M, Harper LM, et al. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the usa: a cross-sectional study. BJOG. 2022;129(3):473–83. doi:10.1111/1471–0528.16960 pmid:34605130

67. Rodriguez MI, Martinez Acevedo A, Swartz JJ, Caughey AB, Valent A, McConnell KJ. Association of prenatal care expansion with use of antidiabetic agents during pregnancies among latina emergency medicaid recipients with gestational diabetes. JAMA Netw Open. 2022;5(4): e229562. doi:10.1001/jamanetworkopen.2022.9562 pmid:35486400

68. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet gynecol. 2020;135(6): e237-e260. doi:10.1097/AOG.0000000000003891 pmid:32443079

69. Attar A, Hosseinpour A, Moghadami M. The impact of antihypertensive treatment of mild to moderate hypertension during pregnancy on maternal and neonatal outcomes: an updated meta-analysis of randomized controlled trials. Clin Cardiol. 2023;46(5):467–76. doi:10.1002/clc.24013 pmid:36987390

70. Garcia JE, Mulrenin IR, Nguyen AB, Loop MS, Daubert MA, Urrutia R, et al. Antihypertensive medication use during pregnancy in a real-world cohort of patients diagnosed with a hypertensive disorder of pregnancy. Front Cardiovasc Med. 2023;10:1225251. doi:10.3389/fcvm.2023.1225251 pmid:37485273

71. Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, Fischer MA. Patterns of outpatient antihypertensive medication use during pregnancy in a medicaid population. Hypertension. 2012;60(4):913–20. doi:10.1161/HYPERTENSIONAHA.112.197095 pmid:22966012

72. Murphy VE, Gibson PG, Schatz M. Managing asthma during pregnancy and the postpartum period. J Allergy Clin Immunol Pract. 2023;11(12):3585–94. doi:10.1016/j.jaip.202r3.07.020 pmid:37482082

73. Murphy VE, Namazy JA, Powell H, Schatz M, Chambers C, Attia J, Gibson PG. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG. 2011;118(11):1314–23. doi:10.1111/j.1471–0528.2011.03055.x pmid:21749633

74. Kemppainen M, Lahesmaa-Korpinen AM, Kauppi P, Virtanen M, Virtanen SM, Karikoski R, et al. Maternal asthma is associated with increased risk of perinatal mortality. PLoS One. 2018;13(5): e0197593. doi:10.1371/journal.pone.0197593 pmid:29775476

75. Cohen JM, Bateman BT, Huybrechts KF, Mogun H, Yland J, Schatz M, et al. Poorly controlled asthma during pregnancy remains common in the united states. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2672–80.e10. doi:10.1016/j.jaip.2019.05.043 pmid:31257187

76. Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. Obstet gynecol. 2021;138(2): e55-e64. doi:10.1097/AOG.0000000000004477 pmid:34293770

77. Detlefs SE, Jochum MD, Salmanian B, McKinney JR, Aagaard KM. The impact of response to iron therapy on maternal and neonatal outcomes among pregnant women with anemia. Am J Obstet Gynecol MFM. 2022;4(2):100569. doi:10.1016/j.ajogmf.2022.100569 pmid:35033748

78. Shevell L, Sood SL; Racial Disparities in Screening and Management of Anemia Among Pregnant Women. Blood 2022;140 (supplement 1):7979–7980. doi: .

79. Society for Maternal-Fetal Medicine; Sinkey RG, Ogunsile FJ, Kanter J, Bean C, Greenberg M; Society for Maternal-Fetal Medicine Publications Committee. Society for maternal-fetal medicine consult series #68: sickle cell disease in pregnancy. Am J Obstet Gynecol. 2024;230(2): B17-B40. doi:10.1016/j.ajog.2023.10.031 pmid:37866731

80. AlMoshary M, Arabdin M. The role of prophylactic transfusion on the maternal and fetal outcomes in pregnant women with sickle cell disease: a systematic review and meta-analysis. Medicine (Baltimore). 2024;103(36): e39475. doi:10.1097/MD.0000000000039475 pmid:39252331

81. Ananthaneni A, Jones S, Ghoweba M, Grant V, Leethy K, Benzar T, et al. Impact of scheduled partial exchange transfusions on outcomes in pregnant patients with severe sickle cell disease: a retrospective study. Hematol Transfus Cell Ther. 2024;46 Suppl 5(Suppl 5): S109-S114. doi:10.1016/j.htct.2024.07.001 pmid:39322530

82. Albright CM, Wenstrom KD. Malignancies in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33:2-18. doi:10.1016/j.bpobgyn.2015.10.004

83. Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30(10):1601–12. doi:10.1093/annonc/mdz228

84. Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29(5):328–34. doi:10.1097/CCO.0000000000000386

85. Salani R, Billingsley CC, Crafton SM. Cancer and pregnancy: an overview for obstetricians and gynecologists. Am J Obstet Gynecol. 2014;211(1):7-14. doi:10.1016/j.ajog.2013.12.002

86. Maggen C, van Gerwen M, Van Calsteren K, Vandenbroucke T, Amant F. Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article. Int J Gynecol Cancer. 2019;29(2):404–16. doi:10.1136/ijgc-2018–000061 pmid:30659032

87. Milosevic B, Likic Ladjevic I, Dotlic J, Beleslin A, Mihaljevic O, Pilic I, et al. Cancer during pregnancy: twenty-two years of experience from a tertiary referral center. Acta Obstet Gynecol Scand. 2024;103(4):716–28. doi:10.1111/aogs.14756 pmid:38216215

88. Metcalfe A, Cairncross ZF, McMorris CA, Friedenreich CM, Nelson G, Bhatti P, et al. Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study. J Natl Cancer Inst. 2025;117(3):554–61. doi:10.1093/jnci/djae273 pmid:39475425

89. Hufstetler K, Llata E, Miele K, Quilter LAS. Clinical updates in sexually transmitted infections, 2024. J Womens Health (Larchmt). 2024;33(6):827–37. doi:10.1089/jwh.2024.0367 pmid:38770770

90. Reese PC. Stis during pregnancy. Am Fam Physician. 2024;109(1):10–2. pmid:38227864

91. Tong H, Heuer A, Walker N. The impact of antibiotic treatment for syphilis, chlamydia, and gonorrhoea during pregnancy on birth outcomes: a systematic review and meta-analysis. J Glob Health. 2023;13:04058. doi:10.7189/jogh.13.04058 pmid:37325885

92. Albert AYK, Elwood C, Wagner EC, Pakzad Z, Chaworth-Musters T, Berg K, et al. Investigation of factors associated with spontaneous preterm birth in pregnant women living with hiv. AIDS. 2020;34(5):719–27. doi:10.1097/QAD.0000000000002464 pmid:31895145

93. Venkatesh KK, Edmonds A, Westreich D, Dionne-Odom J, Weiss DJ, Sheth AN, et al. Associations between hiv, antiretroviral therapy and preterm birth in the us women's interagency hiv study, 1995–2018: a prospective cohort. HIV Med. 2022;23(4):406–16. doi:10.1111/hiv.13171 pmid:34514711

94. Dude AM, Drexler K, Yee LM, Badreldin N. Adherence to sexually transmitted infection screening in pregnancy. J Womens Health (Larchmt). 2023;32(6):652–6. doi:10.1089/jwh.2022.0409 pmid:37083421

95. Centers for Disease Control and Prevention. Sexually transmitted infections surveillance, 2022. Atlanta (GA): U.S. Department of Health and Human Services. 2024 Nov, https: //www.cdc.gov/sti-statistics/media/pdfs/2024/11/2022-STI-Surveillance-Report-PDF.pdf  (accessed 2025 Sep 28).

96. Cohn ER, Korte JE, Lazenby GB. Disparities and delay in the use of guideline-based antiretroviral therapy for treatment of pregnant women with hiv in the southeast united states. AIDS Patient Care STDS. 2019;33(9):381–3. doi:10.1089/apc.2019.0147 pmid:31393173

97. American College of Obstetricians and Gynecologists. Immunization for pregnant women: a call to action. Washington (DC): American College of Obstetricians and Gynecologists https: //www.acog.org/programs/immunization-for-women/activities-initiatives/immunization-for-pregnant-women-a-call-to-action (accessed 2025 Sep 28).

98. Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K, Heath PT. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol. 2022;226(4):459–74. doi:10.1016/j.ajog.2021.10.041 pmid:34774821

99. Influenza in Pregnancy: Prevention and Treatment: ACOG Committee Statement No. 7. Obstet Gynecol. 2024;143(2): e24-e30. doi:10.1097/AOG.0000000000005479 pmid:38016152

100. Bednarek A, Laskowska M. Vaccination guidelines for pregnant women: addressing covid-19 and the omicron variant. Med Sci Monit. 2024;30: e942799. doi:10.12659/MSM.942799 pmid:38229424

101. Ahmed B, Konje JC. Screening for infections in pregnancy - an overview of where we are today. Eur J Obstet Gynecol Reprod Biol. 2021;263:85–93. doi:10.1016/j.ejogrb.2021.06.002 pmid:34171635

102. Badell ML, Prabhu M, Dionne J, Tita ATN, Silverman NS. Society for maternal-fetal medicine consult series #69: hepatitis b in pregnancy: updated guidelines. Am J Obstet Gynecol. 2024;230(4): B2-B11. doi:10.1016/j.ajog.2023.12.023 pmid:38141870

103. Viral Hepatitis in Pregnancy: ACOG Clinical Practice Guideline No. 6. Obstet Gynecol. 2023;142(3):745–59. doi:10.1097/AOG.0000000000005300 pmid:37590986

104. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052–62. doi:10.1002/phar.1649 pmid:26598097

105. Corrales M, Corrales-Acosta E, Corrales-Riveros JG. Which antibiotic for urinary tract infections in pregnancy? a literature review of international guidelines. J Clin Med. 2022;11(23):7226. doi:10.3390/jcm11237226 pmid:36498799

106. Ansaldi Y, Martinez de Tejada Weber B. Urinary tract infections in pregnancy. Clin Microbiol Infect. 2023;29(10):1249–53. doi:10.1016/j.cmi.2022.08.015 pmid:36031053

107. Hui L, Marzan MB, Rolnik DL, Potenza S, Pritchard N, Said JM, et al. Reductions in stillbirths and preterm birth in covid-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes. Am J Obstet Gynecol. 2023;228(5):585.e1-585.e16. doi:10.1016/j.ajog.2022.10.040 pmid:36336084

108. Darwin KC, Kohn JR, Shippey E, Uribe KA, Gaur P, Eke AC. Reduction in preterm birth among covid-19-vaccinated pregnant individuals in the united states. Am J Obstet Gynecol MFM. 2023;5(10):101114. doi:10.1016/j.ajogmf.2023.101114 pmid:37543141

109. Nunes MC, Aqil AR, Omer SB, Madhi SA. The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. Am J Perinatol. 2016;33(11):1104–4. doi:10.1055/s-0036–1586101 pmid:27603545

110. Sangkomkamhang US, Lumbiganon P, Prasertcharoensuk W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. 2015;2015(2): CD006178. doi:10.1002/14651858.CD006178.pub3 pmid:25922860

111. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2019;2019(11): CD000490. doi:10.1002/14651858.CD000490.pub4 pmid:31765489

112. Kahn KE, Garacci E, Razzaghi H, Jatlaoui TC, Skoff TH, Ellington SR, et al. Flu, tdap, and covid19 vaccination coverage among pregnant women — united states, april 2024. Centers for Disease Control and Prevention. https: //www.cdc.gov/fluvaxview/coverage-by-season/pregnant-april-2024.html#cdc_report_pub_study_section_6-tables-and-figures  (accessed 2025 Sep 28).

113. Young EH, Strey KA, Lee GC, Carlson TJ, Koeller JM, Mendoza VM, et al. National disparities in antibiotic prescribing by race, ethnicity, age group, and sex in united states ambulatory care visits, 2009 to 2016. Antibiotics. 2022;12(1):51. doi:10.3390/antibiotics12010051 pmid:36671252

114. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–49. doi:10.5664/jcsm.6470 pmid:27998379

115. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335–43. doi:10.5664/jcsm.7640 pmid:30736887

116. Facco FL, Chan M, Patel SR. Common sleep disorders in pregnancy. Obstet Gynecol. 2022;140(2):321–39. doi:10.1097/AOG.0000000000004866 pmid:35852285

117. Middleton PG. Obstructive sleep apnea and sleep disorders in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2022;85(Pt A):107–13. doi:10.1016/j.bpobgyn.2022.11.004 pmid:36443159

118. McLafferty LP, Spada M, Gopalan P. Pharmacologic treatment of sleep disorders in pregnancy. Sleep Med Clin. 2022;17(3):445–52. doi:10.1016/j.jsmc.2022.06.009 pmid:36150806

119. Lee YC, Chang YC, Tseng LW, Lin WN, Lu CT, Lee LA, et al. Continuous positive airway pressure treatment and hypertensive adverse outcomes in pregnancy: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(8): e2427557. doi:10.1001/jamanetworkopen.2024.27557 pmid:39136943

120. Manber R, Bei B, Simpson N, Asarnow L, Rangel E, Sit A, et al. Cognitive behavioral therapy for prenatal insomnia: a randomized controlled trial. Obstet Gynecol. 2019;133(5):911–9. doi:10.1097/AOG.0000000000003216 pmid:30969203

121. Felder JN, Epel ES, Neuhaus J, Krystal AD, Prather AA. Efficacy of digital cognitive behavioral therapy for the treatment of insomnia symptoms among pregnant women: a randomized clinical trial. JAMA Psychiatry. 2020;77(5):484–92. doi:10.1001/jamapsychiatry.2019.4491 Erratum in: JAMA Psychiatry. 2020;77(7):768. doi:10.1001/jamapsychiatry.2020.0724 pmid:31968068

122. Orbell SL, Scott PW, Baniak LM, Chasens ER, Godzik C, Jeon B, et al. Patient-level factors associated with the self-report of trouble sleeping to healthcare providers in adults at high risk for obstructive sleep apnea. Sleep Health. 2023;9(6):984–90. doi:10.1016/j.sleh.2023.08.007 pmid:37821259

123. Kalmbach DA, Cheng P, Reffi AN, Seymour GM, Ruprich MK, Bazan LF, et al. Racial disparities in treatment engagement and outcomes in digital cognitive behavioral therapy for insomnia among pregnant women. Sleep Health. 2023;9(1):18–25. doi:10.1016/j.sleh.2022.10.010 pmid:36456448

124. Smocot J, Huynh N, Panyarath P, Kimoff RJ, Meltzer S, Drouin-Gagné L, et al. Patterns of adherence to continuous positive airway pressure and mandibular advancement splints in pregnant individuals with sleep-disordered breathing. Sleep Breath. 2025;29(2):148. doi:10.1007/s11325–025-03284-5 pmid:40183988

125. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4. Obstet Gynecol. 2023;141(6):1232–61. doi:10.1097/AOG.0000000000005200 pmid:37486660

126. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141(6):1262–88. doi:10.1097/AOG.0000000000005202 pmid:37486661

127. McKee K, Admon LK, Winkelman TNA, Muzik M, Hall S, Dalton VK, Zivin K. Perinatal mood and anxiety disorders, serious mental illness, and delivery-related health outcomes, united states, 2006–15. BMC Womens Health. 2020;20(1):150. doi:10.1186/s12905–020-00996-6 pmid:32703202

128. Li DK, Ferber JR, Odouli R, Quesenberry C, Avalos L. Comparative effectiveness of treating prenatal depression with counseling versus antidepressants in relation to preterm delivery. Am J Obstet Gynecol. 2025;232(5):494.e1-494.e9. doi:10.1016/j.ajog.2024.08.046 pmid:39218285

129. Davis EP, Demers CH, Deer L, Gallop RJ, Hoffman MC, Grote N, et al. Impact of prenatal maternal depression on gestational length: post hoc analysis of a randomized clinical trial. EClinicalMedicine. 2024;72:102601. doi:10.1016/j.eclinm.2024.102601 pmid:38680516

130. Janssen LE, Gieskes AA, Kok M, de Groot CJM, Oudijk MA, de Boer MA. Stress-reducing interventions in pregnancy for the prevention of preterm birth: a systematic review and meta-analysis. J Psychosom Obstet Gynaecol. 2023;44(1):2281238. doi:10.1080/0167482X.2023.2281238 Erratum in: J Psychosom Obstet Gynaecol. 2024;45(1):2335858. doi:10.1080/0167482X.2024.2335858 pmid:38064297

131. Lau Y, Cheng JY, Wong SH, Yen KY, Cheng LJ. Effectiveness of digital psychotherapeutic intervention among perinatal women: a systematic review and meta-analysis of randomized controlled trials. World J Psychiatry. 2021;11(4):133–52. doi:10.5498/wjp.v11.i4.133 pmid:33889538

132. Abdelhafez MA, Ahmed KM, Ahmed NM, Ismail M, Mohd Daud MNB, Ping NPT, et al. Psychiatric illness and pregnancy: a literature review. Heliyon. 2023;9(11): e20958. doi:10.1016/j.heliyon.2023.e20958 pmid:37954333

133. American Psychiatric Association (APA). Perinatal mental and substance use disorders: a white paper. Arlington, VA: American Psychiatric Association;2023. https: //www.psychiatry.org/getmedia/344c26e2-cdf5-47df-a5d7-a2d444fc1923/APA-CDC-Perinatal-Mental-and-Substance-Use-Disorders-Whitepaper.pdf (accessed 2025 Sep 28).

134. Raffi ER, Nonacs R, Cohen LS. Safety of psychotropic medications during pregnancy. Clin Perinatol. 2019;46(2):215–34. doi:10.1016/j.clp.2019.02.004 pmid:31010557

135. Salameh TN, Hall LA, Crawford TN, Staten RR, Hall MT. Racial/ethnic differences in mental health treatment among a national sample of pregnant women with mental health and/or substance use disorders in the united states. J Psychosom Res. 2019;121:74–80. doi:10.1016/j.jpsychores.2019.03.015 pmid:30928211

136. Addressing Social and Structural Determinants of Health in the Delivery of Reproductive Health Care: ACOG Committee Statement No. 11. Obstet Gynecol. 2024Nov 1;144(5): e113-e120. doi:10.1097/AOG.0000000000005721 pmid:39418666

137. Xie S, Monteiro K, Gjelsvik A. The association between adverse birth outcomes and smoking cessation during pregnancy across the united states-43 states and new york city, 2012–7. Arch Gynecol Obstet. 2023;308(4):1207–15. doi:10.1007/s00404–22-06792-x pmid:36175683

138. Higgins ST, Erath T, Chen FF. Examining u.s. disparities in smoking among rural versus urban women of reproductive age:2002–19. Prev Med. 2024Aug;185:108054. doi:10.1016/j.ypmed.2024.108054 pmid:38914268

139. Scherman A, Tolosa JE, McEvoy C. Smoking cessation in pregnancy: a continuing challenge in the united states. Ther Adv Drug Saf. 2018;9(8):457–74. doi:10.1177/2042098618775366 pmid:30364850

140. Wiles SD, Lee JW, Nelson A, Petersen AB, Singh PN. Racial/ethnic disparities impact the real-world effectiveness of a multicomponent maternal smoking cessation program: findings from the cttp cohort. Matern Child Health J. 2023Nov;27(11):2038–47. doi:10.1007/s10995–023-03753-x pmid:37589829

141. Martin CE, Scialli A, Terplan M. Unmet substance use disorder treatment need among reproductive age women. Drug Alcohol Depend. 2020;206:107679. doi:10.1016/j.drugalcdep.2019.107679 pmid:31740208

142. Landis RK, Stein BD, Dick AW, Griffin BA, Saloner BK, Terplan M, Faherty LJ. Trends and disparities in perinatal opioid use disorder treatment in medicaid, 2007–12. Med Care Res Rev. 2024;81(2):145–55. doi:10.1177/10775587231216515 pmid:38160405

143. Horan H, Thompson A, Willard K, Mobley E, McDaniel J, Robertson E, McIntosh S, Albright DL. Social determinants associated with substance use and treatment seeking in females of reproductive age in the united states. J Womens Health (Larchmt). 2024;33(5):584–93. doi:10.1089/jwh.2023.0559 pmid:38533906

144. Sweeney PJ, Schwartz RM, Mattis NG, Vohr B. The effect of integrating substance abuse treatment with prenatal care on birth outcome. J Perinatol. 2000;20(4):219–4. doi:10.1038/sj.jp.7200357 pmid:10879333

145. Brik M, Sandonis M, Cabeza Oliver C, Temprado J, Hernández Fleury A, Sánchez Echevarria E, et al. Predictors for cannabis cessation during pregnancy: a 10-year cohort study. J Psychosom Obstet Gynaecol. 2024;45(1):2319290. doi:10.1080/0167482X.2024.2319290 pmid:38401055

146. Goodman DJ, Saunders EC, Frew JR, Arsan C, Xie H, Bonasia KL, Flanagan VA, Lord SE, Brunette MF. Integrated vs nonintegrated treatment for perinatal opioid use disorder: retrospective cohort study. Am J Obstet Gynecol MFM. 2022;4(1):100489. doi:10.1016/j.ajogmf.2021.100489 pmid:34543754

147. Shuman CJ, Zhang X, Hall SV, Tilea A, Clark SJ, Vance AJ, et al. Relationship between opioid use disorder during pregnancy, delivery-related outcomes, and healthcare utilization in michigan medicaid, 2012–21. J Subst Use Addict Treat. 2025;175:209720. doi:10.1016/j.josat.2025.209720 pmid:40328372

148. Dejong K, Olyaei A, Lo JO. Alcohol use in pregnancy. Clin Obstet Gynecol. 2019;62(1):142–55. doi:10.1097/GRF.0000000000000414 pmid:30575614

149. Popova S, Dozet D, Pandya E, Sanches M, Brower K, Segura L, Ondersma SJ. Effectiveness of brief alcohol interventions for pregnant women: a systematic literature review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):61. doi:10.1186/s12884–023-05344-8 pmid:36694121

150. Luong J, Board A, Gosdin L, Dunkley J, Thierry JM, Pitasi M, Kim SY. Alcohol use, screening, and brief intervention among pregnant persons - 24 u.s. Jurisdictions, 2017 and 2019. MMWR Morb Mortal Wkly Rep. 2023;72(3):55–62. doi:10.15585/mmwr.mm7203a2 pmid:36656783

151. Cordova-Ramos EG, Koenig R, Silverstein M. Association of eviction during pregnancy with birth outcomes: an issue of health equity. JAMA Pediatr. 2021 May 1;175(5):464-465. doi:10.1001/jamapediatrics.2020.6556 pmid:33646262

152. Krahn J, Vera Caine V, Chaw-Kant J, Singh AE. Housing interventions for homeless, pregnant/parenting women with addictions: a systematic review. Journal of Social Distress and Homelessness. 2018;27(1):75-88. doi:10.1080/10530789.2018.1442186

153. Harville EW, Wallace ME, Theall KP. Eviction as a social determinant of pregnancy health: county-level eviction rates and adverse birth outcomes in the united states. Health Soc Care Community. 2022 Nov;30(6): e5579-e5587. doi:10.1111/hsc.13983 pmid:36065610

154. Stanhope KK, Markowitz S, Kramer MR. Expiration of a state level eviction moratorium in the first or second trimester of pregnancy and perinatal outcomes among medicaid and uninsured people, 2020-2022. Health Place. 2024 Dec 30;91:103408. doi:10.1016/j.healthplace.2024.103408 pmid:39740387

155. Leifheit KM, Chen KL, Anderson NW, Yama C, Sriram A, Pollack CE, et al. Tenant right-to-counsel and adverse birth outcomes in new york, new york. JAMA Pediatr. 2024 Dec 1;178(12):1337-1344. doi:10.1001/jamapediatrics.2024.4699 pmid:39466257

156. Health Policy Institute of Ohio. Healthy beginnings at home pilot: executive summary. Columbus, OH: Health Policy Institute of Ohio;25 Jun 2021. https: //www.healthpolicyohio.org/files/publications/hbahfinalreportesy06.25.2021.pdf (accessed 2025 Sep 28).

157. Fraze TK, Brewster AL, Lewis VA, Beidler LB, Murray GF, Colla CH. Prevalence of screening for food insecurity, housing instability, utility needs, transportation needs, and interpersonal violence by US physician practices and hospitals. JAMA Netw Open. 2019 Sep 4;2(9): e1911514. doi:10.1001/jamanetworkopen.2019.11514 pmid:31532515

158. Peahl AF, Chang C, Daniels G, Stout MJ, Low LK, Chen X, et al. Rates of screening for social determinants of health in pregnancy across a statewide maternity care quality collaborative. Am J Obstet Gynecol. 2024 Feb;230(2):267-269.e3. doi:10.1016/j.ajog.2023.09.091 pmid:37777145

159. Merchant T, Soyemi E, Roytman MV, DiTosto JD, Beestrum M, Niznik CM, et al. Healthcare-based interventions to address food insecurity during pregnancy: a systematic review. Am J Obstet Gynecol MFM. 2023 May;5(5):100884. doi:10.1016/j.ajogmf.2023.100884 pmid:36739912

160. Ridberg RA, Marpadga S, Akers MM, Bell JF, Seligman HK. Fruit and vegetable vouchers in pregnancy: preliminary impact on diet & food security. J Hunger Environ Nutr, 16 (2021), pp. 149-163

161. Hamad R, Collin DF, Baer RJ, Jelliffe-Pawlowski LL. Association of revised WIC food package with perinatal and birth outcomes: a quasi-experimental study. JAMA Pediatr. 2019 Sep 1;173(9):845-852. doi:10.1001/jamapediatrics.2019.1706 pmid:31260072

162. Oliveira V, Frazão E, Frazao E, Smallwood D. National- and state-level estimates of WIC eligibility and WIC program reach in 2021: summary. U.S. Department of Agriculture, Food and Nutrition Service, Office of Policy Support. February 2023. https: //fns-prod.azureedge.us/sites/default/files/resource-files/wic-eligibility-report-summary-2021.pdf (accessed 2025 Sep 28).

163. Chisholm CA, Bullock L, Ferguson JEJ 2nd. Intimate partner violence and pregnancy: epidemiology and impact. Am J Obstet Gynecol. 2017 Aug;217(2):141-144. doi:10.1016/j.ajog.2017.05.042 pmid:28551446

164. Price A, Couch K. Patient-centered intimate partner violence screening, brief intervention, and referral to treatment. Nurs Womens Health. 2023 Aug;27(4):291-300. doi:10.1016/j.nwh.2023.02.005 pmid:37321558

165. Stanhope KK, Goebel A, Simmonds M, Timi P, Das S, Immanuelle A, et al. The impact of screening for social risks on obgyn patients and providers: a systematic review of current evidence and key gaps. J Natl Med Assoc. 2023 Aug;115(4):405-420. doi:10.1016/j.jnma.2023.06.002 pmid:37330393

166. Skolarus LE, Williams LS. Implementation research: an approach to overcoming the know-do gap. Lancet Neurol. 2024 Jul;23(7):656-658. doi:10.1016/S1474-4422(24)00219-9 pmid:38876733

167. Tesfalul MA, Feuer SK, Castillo E, Coleman-Phox K, O'Leary A, Kuppermann M. Patient and provider perspectives on preterm birth risk assessment and communication. Patient Educ Couns. 2021 Nov;104(11):2814-2823. doi:10.1016/j.pec.2021.03.038 pmid:33892976

168. Timothy K, Lloyd B, Bradshaw C. Healthcare professionals' perceptions of risk management on pregnancy and childbirth: an integrative review. Midwifery. 2025 Jun;145:104376. doi:10.1016/j.midw.2025.104376 pmid:40117756

169. Smith KL, Shipchandler F, Kudumu M, Davies-Balch S, Leonard SA. "ignored and invisible": perspectives from black women, clinicians, and community-based organizations for reducing preterm birth. Matern Child Health J. 2022 Apr;26(4):726-735. doi:10.1007/s10995-021-03367-1 pmid: n35072869.

170. Gregory EF, Johnson GT, Barreto A, Zakama AK, Maddox AI, Levine LD, et al. Communication and birth experiences among black birthing people who experienced preterm birth. Ann Fam Med. 2024 Jan-Feb;22(1):31-36. doi:10.1370/afm.3048 pmid:38253494

171. Helou A, Stewart K, Ryan K, George J. Pregnant women's experiences with the management of hypertensive disorders of pregnancy: a qualitative study. BMC Health Serv Res. 2021 Dec 2;21(1):1292. doi:10.1186/s12913-021-07320-4 pmid:34856992

172. Zahroh RI, Hazfiarini A, Eddy KE, Vogel JP, Tunçalp Ö, Minckas N, et al. Factors influencing appropriate use of interventions for management of women experiencing preterm birth: a mixed-methods systematic review and narrative synthesis. PLoS Med. 2022 Aug 23;19(8): e1004074. doi:10.1371/journal.pmed.1004074 Erratum in: PLoS Med. 2022 Sep 22;19(9): e1004105. doi:10.1371/journal.pmed.1004105 pmid:35998205

173. Muche AA, Baruda LL, Pons-Duran C, Fite RO, Gelaye KA, Yalew AW, et al. Prognostic prediction models for adverse birth outcomes: a systematic review. J Glob Health. 2024 Oct 25;14:04214. doi:10.7189/jogh.14.04214 pmid:39450618

174. Yan C, Yang Q, Li R, Yang A, Fu Y, Wang J, et al. A systematic review of prediction models for spontaneous preterm birth in singleton asymptomatic pregnant women with risk factors. Heliyon. 2023 Sep 13;9(9): e20099. doi:10.1016/j.heliyon.2023.e20099 pmid:37809403

175. Wahab RJ, Jaddoe VWV, van Klaveren D, Vermeulen MJ, Reiss IKM, Steegers EAP, et al. Preconception and early-pregnancy risk prediction for birth complications: development of prediction models within a population-based prospective cohort. BMC Pregnancy Childbirth. 2022 Feb 28;22(1):165. doi:10.1186/s12884-022-04497-2 pmid:35227240

176. Shields LB, Weymouth C, Bramer KL, Robinson S, McGee D, Richards L, et al. Risk assessment of preterm birth through identification and stratification of pregnancies using a real-time scoring algorithm. SAGE Open Med. 2021 Jan 12;9:2050312120986729. doi:10.1177/2050312120986729 pmid:33489231

177. Baer RJ, McLemore MR, Adler N, Oltman SP, Chambers BD, Kuppermann M, et al. Pre-pregnancy or first-trimester risk scoring to identify women at high risk of preterm birth. Eur J Obstet Gynecol Reprod Biol. 2018 Dec;231:235-240. doi:10.1016/j.ejogrb.2018.11.004 pmid:30439652

178. Meertens LJE, van Montfort P, Scheepers HCJ, van Kuijk SMJ, Aardenburg R, Langenveld J, et al. Prediction models for the risk of spontaneous preterm birth based on maternal characteristics: a

systematic review and independent external validation. Acta Obstet Gynecol Scand. 2018 Aug;97(8):907-920. doi:10.1111/aogs.13358 pmid:29663314

179. Tailored Prenatal Care Delivery for Pregnant Individuals: ACOG Clinical Consensus No. 8. Obstet Gynecol. 2025 May 17;145(5):565-577. doi:10.1097/AOG.0000000000005889 pmid:40245426

180. Greenberg MB, Gandhi M, Davidson C, Carter EB; Publications Committee. Society for maternal-fetal medicine consult series #62: best practices in equitable care delivery-addressing systemic racism and other social determinants of health as causes of obstetrical disparities. Am J Obstet Gynecol. 2022 Aug;227(2): B44-B59. doi:10.1016/j.ajog.2022.04.001 pmid:35378098

181. Grobman WA, Entringer S, Headen I, Janevic T, Kahn RS, Simhan H, et al. Social determinants of health and obstetric outcomes: a report and recommendations of the workshop of the society for maternal-fetal medicine. Am J Obstet Gynecol. 2024 Feb;230(2): B2-B16. doi:10.1016/j.ajog.2023.10.013 pmid:37832813

182. Combs CA, Kumar NR, Morgan JL; SMFM Patient Safety and Quality Committee. Society for maternal-fetal medicine special statement: prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement. Am J Obstet Gynecol. 2023 Aug;229(2): B2-B9. doi:10.1016/j.ajog.2023.04.039 pmid:37146704

183. Crear-Perry J, Correa-de-Araujo R, Lewis Johnson T, McLemore MR, Neilson E, Wallace M. Social and structural determinants of health inequities in maternal health. J Womens Health (Larchmt). 2021 Feb;30(2):230-235. doi:10.1089/jwh.2020.8882 pmid:33181043

184. Combs CA, Zupancic JAF, Walker M, Shi J. Prediction and prevention of preterm birth: secondary analysis of a randomized intervention trial. J Clin Med. 2023 Aug 23;12(17):5459. doi:10.3390/jcm12175459 pmid:37685526

185. Oskovi Kaplan ZA, Ozgu-Erdinc AS. Prediction of preterm birth: maternal characteristics, ultrasound markers, and biomarkers: an updated overview. J Pregnancy. 2018 Oct 10;2018:8367571. doi:10.1155/2018/8367571 pmid:30405914

186. Jelliffe-Pawlowski LL, Rand L, Bedell B, Baer RJ, Oltman SP, Norton ME, Shaw GM, Stevenson DK, Murray JC, Ryckman KK. Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics. J Perinatol. 2018 Aug;38(8):963-972. doi:10.1038/s41372-018-0112-0 Erratum in: J Perinatol. 2018 Jul;38(7):946. doi:10.1038/s41372-018-0158-z pmid:29795450

187. California Birth Certificate Files. Live births, 2016-2020. California Department of Public Health, Vital Records. https: //www.cdph.ca.gov/Programs/CHSI/pages/Vital-Records.aspx (accessed 2025 September 28).

188. Hospital Discharge Records. Live births, 2016-2020. California Department of Health Care Access and Information (HCAI). https: //hcai.ca.gov (accessed 2025 September 28).

189. Baer RJ, Bandoli G, Jelliffe-Pawlowski L, Chambers CD. The university of california study of outcomes in mothers and infants (a population-based research resource): retrospective cohort study. JMIR Public Health Surveill. 2024 Dec 3;10: e59844. doi:10.2196/59844 pmid:39625748

190. Centers for Medicare & Medicaid Services. International classification of diseases, ninth revision, clinical modification (ICD 9 cm). U.S. Department of Health and Human Services. https: //www.cms.gov/medicare/coordination-benefits-recovery/overview/icd-code-lists (accessed 2025 September 28).

191. Centers for Medicare & Medicaid Services. International classification of diseases, tenth revision, clinical modification (ICD 10 cm). U.S. Department of Health and Human Services. https: //www.cms.gov/medicare/coordination-benefits-recovery/overview/icd-code-lists (accessed 2025 September 28).

192. U.S. Department of agriculture, food and nutrition service. (2024). WIC – The Special Supplemental Nutrition Program for Women, Infants, and Children. https: //www.fns.usda.gov/wic (accessed 2025 September 28).

193. Committee Opinion No 700: Methods for Estimating the Due Date. Obstet gynecol. 2017 May;129(5): e150-e154. doi:10.1097/AOG.0000000000002046 pmid:28426621

194. U.S. Centers for disease control and prevention. Severe maternal morbidity (SMM). Maternal Infant Health – Public Health & Professional [Internet]. 2024 May 15. https: //www.cdc.gov/maternal-infant-health/php/severe-maternal-morbidity/index.htm (accessed 2025 September 28).

195. Talge NM, Mudd LM, Sikorskii A, et al. United states birth weight reference corrected for implausible gestational age estimates. Pediatrics. 2014;133(5):844-53. doi:10.1542/peds.2013-3285 pmid:24777216

196. Oehlert GW. A note on the delta method. Am Stat. 1992;46(1):27-29. doi:10.1080/00031305.1992.10475842

197. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. Epidemiology. 2007 Nov;18(6):800-4. doi:10.1097/EDE.0b013e3181577654 pmid:18049194

198. Tang ID, Mallia D, Yan Q, Pe'er I, Raja A, Salleb-Aouissi A et al. Scoping review of preterm birth risk factors. Am J Perinatol. 2024 May;41(S01): e2804-e2817. doi:10.1055/s-0043-1775564 pmid:37748506

199. Koivu A, Sairanen M. Predicting risk of stillbirth and preterm pregnancies with machine learning. Health Inf Sci Syst. 2020 Mar 25;8(1):14. doi:10.1007/s13755-020-00105-9 pmid:32226625

200. Mehta-Lee SS, Palma A, Bernstein PS, Lounsbury D, Schlecht NF. A preconception nomogram to predict preterm delivery. Matern Child Health J. 2017 Jan;21(1):118-127. doi:10.1007/s10995-016-2100-3 pmid:27461021

201. van Eekhout JCA, Becking EC, Scheffer PG, Koutsoliakos I, Bax CJ, Henneman L et al. First-trimester prediction models based on maternal characteristics for adverse pregnancy outcomes: a systematic review and meta analysis. BJOG. 2025 Feb;132(3):243-265. doi:10.1111/1471-0528.17983 pmid:39449094

202. Zhang Y, Sylvester KG, Wong RJ, Blumenfeld YJ, Hwa KY, Chou CJ et al. Prediction of risk for early or very early preterm births using high-resolution urinary metabolomic profiling. BMC Pregnancy Childbirth. 2024 Nov 25;24(1):783. doi:10.1186/s12884-024-06974-2 pmid:39587571

203. Kim JI, Lee JY. Systematic review of prediction models for preterm birth using charms. Biol Res Nurs. 2021 Oct;23(4):708-722. doi:10.1177/10998004211025641 pmid:34159815

204. Sjaarda LA, Radin RG, Silver RM, Mitchell E, Mumford SL, Wilcox B et al. Preconception low-dose aspirin restores diminished pregnancy and live birth rates in women with low-grade inflammation: a secondary analysis of a randomized trial. J Clin Endocrinol Metab. 2017 May 1;102(5):1495-1504. doi:10.1210/jc.2016-2917 pmid:28323989

205. Miller ES, Grobman WA, Culhane J, Adam E, Buss C, Entringer S et al. Antenatal depression, psychotropic medication use, and inflammation among pregnant women. Arch Womens Ment Health. 2018 Dec;21(6):785-790. doi:10.1007/s00737-018-0855-9 pmid:29862416

206. Tiruneh SA, Vu TTT, Moran LJ, Callander EJ, Allotey J, Thangaratinam S, Rolnik DL, Teede HJ, Wang R, Enticott J. Externally validated prediction models for pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2024 May;63(5):592-604. doi:10.1002/uog.27490 pmid:37724649

207. Sovio U, Smith G. Evaluation of a simple risk score to predict preterm pre-eclampsia using maternal characteristics: a prospective cohort study. BJOG. 2019 Jul;126(8):963-970. doi:10.1111/1471-0528.15664 pmid:30801934

208. Zhang Y, Ding W, Wu T, Wu S, Wang H, Fawad M et al. Pregnancy with multiple high-risk factors: a systematic review and meta-analysis. J Glob Health. 2025 Feb 7;15:04027. doi:10.7189/jogh.15.04027 pmid:39913559

209. Bestman PL, Kolleh EM, Moeng E, Brhane T, Nget M, Luo J. Association between multimorbidity of pregnancy and adverse birth outcomes: a systemic review and meta-analysis. Prev Med. 2024 Mar;180:107872. doi:10.1016/j.ypmed.2024.107872 pmid:38272269

210. McElrath TF, Jeyabalan A, Khodursky A, Moe AB, Lee M, Jain M et al. Utility of the US preventive services task force for preeclampsia risk assessment and aspirin prophylaxis. JAMA Netw Open. 2025 Jul 1;8(7): e2521792. doi:10.1001/jamanetworkopen.2025.21792 Erratum in: JAMA Netw Open. 2025 Aug 1;8(8): e2530317. doi:10.1001/jamanetworkopen.2025.30317 pmid:40674048

211. Burchard J, Polpitiya AD, Fox AC, Randolph TL, Fleischer TC, Dufford MT et al. Clinical validation of a proteomic biomarker threshold for increased risk of spontaneous preterm birth and associated clinical outcomes: a replication study. J Clin Med. 2021 Oct 29;10(21):5088. doi:10.3390/jcm10215088 pmid:34768605

212. Buciu VB, Novacescu D, Zara F, Şerban DM, Tomescu L, Ciurescu S et al. Development of a risk score for the prediction and management of pre-eclampsia in low-resource settings. J Clin Med. 2025 May 13;14(10):3398. doi:10.3390/jcm14103398 pmid:40429393

213. Hoffman MK. Prediction and prevention of spontaneous preterm birth: acog practice bulletin, number 234. Obstet Gynecol. 2021 Dec 1;138(6):945-946. doi:10.1097/AOG.0000000000004612 pmid:34794160

214. Tucker Edmonds B, McKenzie F, Farrow V, Raglan G, Schulkin J. A national survey of obstetricians' attitudes toward and practice of periviable intervention. J Perinatol. 2015 May;35(5):338-43. doi:10.1038/jp.2014.201 pmid:25357097

215. Zahroh RI, Hazfiarini A, Eddy KE, Vogel JP, Tunçalp Ö, Minckas N et al. Factors influencing appropriate use of interventions for management of women experiencing preterm birth: a mixed-methods systematic review and narrative synthesis. PLoS Med. 2022 Aug 23;19(8): e1004074. doi:10.1371/journal.pmed.1004074 Erratum in: PLoS Med. 2022 Sep 22;19(9): e1004105. doi:10.1371/journal.pmed.1004105 pmid:35998205

216. Kaplan HC, Sherman SN, Cleveland C, Goldenhar LM, Lannon CM, Bailit JL.Reliable implementation of evidence: a qualitative study of antenatal corticosteroid administration in Ohio hospitals. Bmj qual saf. 2016 Mar;25(3):173-81. doi:10.1136/bmjqs-2015-003984 pmid:26056321

217. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009 Jul;20(4):488-95. doi:10.1097/EDE.0b013e3181a819a1 pmid:19525685

218. Cole SR, Hernán MA. Fallibility in estimating direct effects. Int J Epidemiol. 2002 Feb;31(1):163-5. doi:10.1093/ije/31.1.163 pmid:11914314

219. Younes S, Samara M, Al-Jurf R, Nasrallah G, Al-Obaidly S, Salama H et al. Incidence, risk factors, and outcomes of preterm and early term births: a population-based register study. Int J Environ Res Public Health. 2021 May 29;18(11):5865. doi:10.3390/ijerph18115865 pmid:34072575

220. Yang J, Baer RJ, Berghella V, Chambers C, Chung P, Coker T et al. Recurrence of preterm birth and early term birth. Obstet Gynecol. 2016 Aug;128(2):364-372. doi:10.1097/AOG.0000000000001506 pmid:27400000

221. Hong J, Crawford K, Jarrett K, Triggs T, Kumar S. Five-minute apgar score and risk of neonatal mortality, severe neurological morbidity and severe non-neurological morbidity in term infants - an australian population-based cohort study. Lancet Reg Health West Pac. 2024 Jan 13;44:101011. doi:10.1016/j.lanwpc.2024.101011 pmid:38292653

222. Arham M, Wróblewska-Seniuk K. Short- and long-term consequences of late-preterm and early-term birth. Children (Basel). 2025 Jul 9;12(7):907. doi:10.3390/children12070907 pmid:40723099

223. Baer RJ, Rogers EE, Partridge JC, Anderson JG, Morris M, Kuppermann M et al. Population-based risks of mortality and preterm morbidity by gestational age and birth weight. J Perinatol. 2016 Nov;36(11):1008-1013. doi:10.1038/jp.2016.118 pmid:27467566

224. Declercq E, Liu CL, Cabral HJ, Amutah-Onukagha N, Hwang S, Diop H. Relationship between maternal death and infant outcomes in a longitudinal, population-based dataset. Obstet Gynecol. 2025 Sep 25:10.1097/AOG.0000000000006071. doi:10.1097/AOG.0000000000006071 pmid:40997329

225. Steurer MA, Baer RJ, Chambers CD, Costello J, Franck LS, McKenzie-Sampson S, et al. Mortality and major neonatal morbidity in preterm infants with serious congenital heart disease. J Pediatr. 2021 Dec;239:110-116.e3. doi:10.1016/j.jpeds.2021.08.039 pmid:34454949

226. Korzeniewski SJ, Sutton E, Escudero C, Roberts JM. The global pregnancy collaboration (colab) symposium on short- and long-term outcomes in offspring whose mothers had preeclampsia: a scoping review of clinical evidence. Front Med (Lausanne). 2022 Aug 30;9:984291. doi:10.3389/fmed.2022.984291 pmid:36111112

227. Zhong W, Zhu F, Li S, Chen J, He F, Xin J, Yang M. Maternal and neonatal outcomes after planned or emergency delivery for placenta accreta spectrum: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Sep 28;8:731412. doi:10.3389/fmed.2021.731412 pmid:34650996

228. Wolfson C, Angelson JT, Forrest AD, Michos ED, Ahmed S, Aina-Mumuney A, et al. Comorbidities and pregnancy-related risk factors in patients with severe maternal morbidity: application of a validated obstetrical comorbidity scoring system to a surveillance-identified population. Healthcare (Basel). 2025 Sep 18;13(18):2351. doi:10.3390/healthcare13182351 pmid:41008483

229. Akintunde TB, Senior MA, Logan A, Alfred MC. Systems factors contributing to racial/ethnic disparities in maternal health: a systematic review. J Racial Ethn Health Disparities. 2025 Aug 11. doi:10.1007/s40615-025-02583-7 pmid:40789815

230. Sui H, Du M, Chen J, Yang R, Shi B, Huang H, Wang Y. The impact of maternal systemic diseases on the occurrence of cleft lip and palate in newborns: a narrative review. Front Public Health. 2025 Aug 1;13:1568140. doi:10.3389/fpubh.2025.1568140 pmid:40823220

231. Buczyńska A, Sidorkiewicz I, Kosiński P, Krętowski AJ, Zbucka-Krętowska M. Integrative review of molecular, metabolic, and environmental factors in spina bifida and congenital diaphragmatic hernia: insights into mechanisms and emerging therapeutics. Cells. 2025 Jul 10;14(14):1059. doi:10.3390/cells14141059 pmid:40710310

232. Frey HA, Ashmead R, Farmer A, Kim YH, Shellhaas C, Oza-Frank R et al. A prediction model for severe maternal morbidity and mortality after delivery hospitalization. Obstet Gynecol. 2023 Sep 1;142(3):585-593. doi:10.1097/AOG.0000000000005281 pmid:37535951

233. Vasudevan L, Kibria MG, Kucirka LM, Shieh K, Wei M, Masoumi S, Balasubramanian S, Victor A, Conklin JL, Gurcan MN, Stuebe AM, Page D. Machine learning models to predict risk of maternal morbidity and mortality from electronic medical record data: scoping review. J Med Internet Res. 2025 Aug 14;27: e68225. doi:10.2196/68225 pmid:40811480

**Table 1.** Actionable risk factors for preterm birth considered in the present study and known treatments.

| Risk Factor(s) | Treatment(s) where Indicated |
|---|---|
| **≥ 1 High Risk Factor(s) for Preeclampsia**[a] [38] | LDA started by 12-28 weeks gestation [38] |
| Pre-Gestational Diabetes | LDA+ (for Type 1/Insulin dependent, continuous glucose monitoring (CGM)) [38,42] |
| Chronic Hypertension (cHTN) | LDA+ antihypertensive medications [45,46] |
| Autoimmune Disorder | LDA+ DX-specific medications, management [50] |
| Kidney Disease | LDA+DX-specific medications/ dialysis [54,55] |
| **≥ 2 Moderate Risk Factors for Preeclampsia**[b] [38] | LDA started by 12-28 weeks gestation [38] |
| Previous Spontaneous PTB[c] | LDA (with at least one other moderate risk factor)+ if short cervix (<25mm), vaginal Progesterone or cerclage [58,59] |
| **Gestational Diabetes** | Diet+activity and Insulin, Metformin, or Glyburide |
| **Severe Gestational Hypertension** | Antihypertensive medications |
| **Asthma** | Inhaled corticosteroids or other medications |
| **Anemia** | Oral iron therapy, transfusions |
| **Sickle-Cell Anemia** | Vaccinations, non-Iron-containing supplements, transfusions |
| **Cancer/Malignancy** | Surgery/ medications/ treatments |
| **Sexually Transmitted Infection (STI)** | Screening and medications |
| **Other infection (not STI)**[e] | Vaccination/ screening/ medications |
| **Insomnia or Other Sleep Disorder** | Continuous positive airway pressure (CPAP), Cognitive Behavioral Therapy (CBT), medications |
| **Mental Health Condition (e.g. depression, anxiety, bipolar-disorder)** | CBT/ psychotherapy, medications (e.g. antidepressants, antipsychotics, mood stabilizers), general stress reduction |
| **Smoking/ Vaping Tobacco** | Cessation, counseling, referral, uptake of smoking cessation |
| **Drug Use (Cannabis, Other)** | Counseling/ treatment |
| **Alcohol Use** | Screening/ counseling |
| **Homelessness/ Housing Insecurity** | Screening/ policies/ referral for housing services |
| **Hunger/ Food Insecurity** | Screening/ food supplements/ vouchers/ WIC enrollment, other referral |
| **Intimate Partner/Domestic Violence** | Screening/ referral |

CBT, Cognitive Behavioral Therapy; CPAP, Continuous Positive Airway Pressure; LDA, low dose aspirin; PTB, preterm birth (gestational weeks < 37); STI, sexually transmitted infection; WIC, Supplemental Nutrition Program for Women, Infants, and Children

[a]Pre-gestational Diabetes; Chronic Hypertension; Renal/Kidney Disease; Autoimmune Disorder (history of preeclampsia also an indicator but not captured in current study)
[b]Nulliparous (first time pregnancy); Obesity (body mass index ≥30+); Age >34 years; Any previous adverse pregnancy outcome (e.g. miscarriage, stillbirth, preterm birth); >10-years since last pregnancy (interpregnancy interval); Use of in-vitro fertilization (IVF); Low

Income; Black/ African American race/ethnicity; Family history of preeclampsia (mother, sister) also an indicator but not captured in current study

[c]Contractions and/or rupture of membranes and/or water broke before expected and previously gave birth before 37 weeks

[d]Systolic blood pressure of 160 mm Hg or more and/or diastolic blood pressure of 110 mm Hg or more [68]

[e]For example, urinary tract infection (UTI), other bacterial infection, other viral infection

[f]Not captured in the current study, housing insecurity used as a proxy

**Table 2.** Sample characteristics, California singleton births in 2016-2019 (training dataset) and in 2020 (testing dataset).

| | Training | Testing |
|---|---|---|
| | n = (%) | n = (%) |
| **Sample** | 1,568,976 (100.0) | 338,109 (100.0) |
| **Maternal Age (Years)** | | |
| <18 | 16,283 (1.0) | 2,904 (0.9) |
| 18-34 | 1,191,026 (75.9) | 251,022 (74.2) |
| ≥34 | 361,621 (23.1) | 84,183 (24.9) |
| **Parity** | | |
| 0 | 603,985 (38.5) | 133,171 (39.4) |
| ≥1 | 964,991 (61.5) | 204,938 (60.6) |
| **Race/Ethnicity** | | |
| Hispanic | 745,823 (47.5) | 161,711 (47.8) |
| Non-Hispanic | | |
| American Indian/Alaska Native | 4,751 (0.3) | 1,063 (0.3) |
| Asian | 241,436 (15.4) | 46,618 (13.8) |
| Black/African American | 72,696 (4.6) | 15,775 (4.7) |
| Hawaiian/Pacific Islander | 5,448 (0.4) | 1,118 (0.3) |
| White | 412,411 (26.3) | 89,576 (26.5) |
| Other[a] | 86,411 (5.5) | 22,248 (6.6) |
| ≥2 Race/Ethnicities | 36,244 (2.3) | 7,811 (2.3) |
| **Public Insurance**[b] | | |
| Yes | 618,704 (43.5) | 140,288 (41.5) |
| No | 887,272 (56.6) | 197,821 (58.5) |
| **Education (Years)** | | |
| <12 | 205,927 (13.1) | 38,247 (11.3) |
| 12 | 376,264 (24.0) | 81,634 (24.1) |
| >12 | 905,930 (57.7) | 196,688 (58.2) |
| **Preterm Birth** | | |
| Any (<37 weeks) | 109,526 (7.0) | 24,251 (7.2) |
| <32 weeks | 13,467 (0.9) | 3,177 (0.9) |
| 32-36 weeks | 96,059 (6.1) | 21,074 (6.2) |
| **Term, Adverse Outcome**[c] | 538,651(34.3) | 119,725 (35.4) |
| **Term, No Adverse Outcome** | 920,799 (58.7) | 194,133 (57.4) |

[a]Indian (Asian)', 'Filipino', 'Other-specified', 'Refused to state', 'Unknown'
[b]Health insurance through the state MediCal (California Medicaid) program
[c]Birth at 37 or more weeks, one or more of the following: early term birth (37-38 Weeks), low birth weight (LBW, <2500 grams), small for gestational age (SGA) [195], preeclampsia, other placental problem (previa, abruption, accreta), severe maternal morbidity (SMM) [194], major structural birth defect, maternal death <1 year postpartum, infant death <1 year (additional detail for variable coding including in Supplemental Table 2).

**Table 3.** Association between actionable risk factors and preterm birth: California singleton births 2016-2019 (training)[a].

| | Preterm Birth | Term, No Adverse[b] | | |
|---|---|---|---|---|
| | n = % | n = % | RR (95% CI) | β |
| **Sample** | 109,526 (100.0) | 920,799 (100.0) | | |
| **Risk Factor(s)** | | | | |
| ≥ 1 High Risk Factor(s) for Preeclampsia[c]; No Moderate ≥ 2[d] | 3,358 (3.1) | 8,750 (1.0) | 4.52 (4.35, 4.69) | 1.509 |
| ≥ 2 Moderate Risk Factors for Preeclampsia[d;] No High Risk[c] | 53,638 (49.0) | 494,331 (43.9) | 1.91 (1.88, 1.94) | 0.647 |
| ≥ 1 High Risk Factor(s) for Preeclampsia[c,] ≥ 2 Moderate Risks[d] | 9,324 (8.5) | 13,259 (1.4) | 6.73 (6.57, 6.89) | 1.898 |
| | Mean (SD) | Mean (SD) | | |
| **Number of High Risk Factors for Preeclampsia[c]** | 0.13 (0.40) | 0.03 (0.16) | 2.88 (2.84, 2.92) | 1.058 |
| **Number of Moderate Risk Factors for > 2 Preeclampsia[d]** | 1.74 (0.95) | 1.46 (0.89) | 1.35 (1.34, 1.36) | 0.300 |
| | n = % | n = % | | |
| **Previous Preterm Birth** | 4,399 (4.0) | 5,629 (0.6) | 4.26 (4.13, 4.39) | 1.449 |
| **Gestational Diabetes** | 14,891 (13.6) | 78,826 (8.2) | 1.63 (1.60, 1.66) | 0.488 |
| **Gestational Hypertension** | 16,907 (15.4) | 27,887 (3.0) | 4.26 (4.13, 4.39) | 1.390 |
| **Asthma** | 8,381 (7.7) | 49,387 (5.4) | 1.40 (1.36, 1.43) | 0.333 |
| **Anemia** | 14,486 (13.2) | 94,727 (10.3) | 1.29 (1.26, 1.31) | 0.251 |
| **Sickle-Cell Anemia** | 74 (0.07) | 157 (0.02) | 3.02 (2.40, 3.79) | 1.104 |
| **Cancer/Malignancy** | 233 (0.2) | 451 (0.1) | 3.21 (2.82, 3.65) | 1.166 |
| **Sexually Transmitted Infection (STI)** | 2,077 (1.9) | 13,573 (1.5) | 1.25 (1.20, 1.31) | 0.226 |
| **Other infection (not STI)[e]** | 18,311 (16.7) | 82,444 (9.0) | 1.85 (1.82, 1.88) | 0.616 |
| **Insomnia or Other Sleep Disorder** | 709 (0.7) | 2,096 (0.2) | 2.39 (2.22, 2.57) | 0.870 |

| | | | | |
|---|---|---|---|---|
| **Mental Health Condition (e.g. depression, anxiety)** | 15,958 (14.6) | 74,763 (8.1) | 1.77 (1.74, 1.80) | 0.569 |
| **Smoking/ Vaping Tobacco** | 4,977 (4.5) | 19,081 (2.1) | 1.99 (1.94, 2.05) | 0.689 |
| **Drug Use (Cannabis, Other)** | 6,127 (5.6) | 14,616 (1.6) | 2.88 (2.81, 2.90) | 1.059 |
| **Alcohol Use** | 399 (0.4) | 1,368 (0.2) | 2.13 (1.93, 2.35) | 0.755 |
| **Homelessness/ Housing Insecurity**[f] | 672 (0.6) | 1,004 (0.1) | 3.79 (3.51, 4.09) | 1.352 |
| **Intimate Partner/ Domestic Violence** | 112 (0.8) | 423 (0.05) | 1.97 (1.64, 2.37) | 0.678 |

β, beta coefficient; CI, confidence interval; RR, relative risk; STI, sexually transmitted infection

[a]Coding schema for summary variables provided in Supplemental Table 2.

[b]Term birth (≥ 37 weeks) without any of the following: early term birth (37–38 weeks), low birthweight (LBW; <2,500 grams), small-for-gestational-age birth (SGA; birth weight <10th percentile for gestational age and sex [195]), preeclampsia, "other placental problems" (placenta previa, placental abruption, or placental accreta), SMM [194], major structural congenital anomaly in the infant, maternal death (<1 year postpartum), or infant death < 1 year (see Supplemental Table 2 for additional coding details).

[c]Pregestational Diabetes; Chronic Hypertension; Renal/Kidney Disease; Autoimmune Disorder (history of preeclampsia also an indicator but not captured in current study)

[d]Nulliparous (first time pregnancy); Obesity (body mass index ≥30+); Age >34 years; Any previous adverse pregnancy outcome (e.g. miscarriage, stillbirth, preterm birth); >10-years since last pregnancy (interpregnancy interval); Use of in-vitro fertilization (IVF); Low Income; Black/ African American race/ethnicity; Family history of preeclampsia (mother, sister) also an indicator but not captured in current study

[e]For example, urinary tract infection (UTI), other bacterial infection, other viral infection

[f]Also used as a proxy for food insecurity

**Table 4.** Association between per-unit increase in <20- and ≥20-week PTB-ARIx score and risk of preterm birth, preeclampsia, and term birth with other adverse outcomes[a] (versus term birth without adverse outcome) in the training and testing samples.

| PTB-ARIx Score | <20 Week | | ≥20 Week | |
|---|---|---|---|---|
| | **Training** RR (95% CI) | **Testing** RR (95% CI) | **Training** RR (95% CI) | **Testing** RR (95% CI) |
| **Any (<37 weeks)[a]** | 1.67 (1.67, 1.68) | 1.66 (1.64, 1.68) | 1.72 (1.71, 1.72) | 1.67 (1.66, 1.69) |
| Spontaneous | 1.91 (1.89, 1.93) | 1.99 (1.96, 2.03) | 1.99 (1.97, 2.00) | 2.03 (2.00, 2.07) |
| Medically-Indicated | 2.14 (2.12, 2.16) | 2.27 (2.23, 2.31) | 2.33 (2.32, 2.35) | 2.43 (2.39, 2.47) |
| **<32 weeks[a]** | 2.17 (2.14, 2.19) | 2.08 (2.03, 2.13) | 2.17 (2.15, 2.20) | 2.05 (2.00, 2.10) |
| Spontaneous | 2.36 (2.31, 2.41) | 2.79 (2.72, 2.85) | 2.38 (2.33, 2.42) | 2.43 (2.33, 2.55) |
| Medically-Indicated | 2.00 (1.95, 2.04) | 2.91 (2.77, 3.05) | 3.06 (2.99, 3.12) | 3.11 (2.98, 3.20) |
| **32-36 weeks[a]** | 1.67 (1.66, 1.68) | 1.68 (1.66, 1.70) | 1.73 (1.72, 1.74) | 1.70 (1.68, 1.71) |
| Spontaneous | 1.89 (1.88, 1.91) | 1.99 (1.95, 2.04) | 1.99 (1.97, 2.00) | 2.04 (2.01, 2.08) |
| Medically-Indicated | 2.11 (2.09, 2.13) | 2.27 (2.23, 2.32) | 2.32 (2.30, 2.34) | 2.44 (2.40, 2.42) |
| **Preeclampsia (Any)** | 1.96 (1.95, 1.97) | 1.89 (1.88, 1.92) | 2.44 (2.43, 2.45) | 2.31 (2.29, 2.33) |
| <32 Weeks | 2.91 (2.85, 2.97) | 2.91 (2.79, 3.02) | 3.27 (3.21, 3.32) | 3.27 (3.16, 3.39) |
| 32-36 Weeks | 2.42 (2.40, 2.45) | 2.49 (2.45, 2.54) | 2.82 (2.80, 2.84) | 2.80 (2.76, 2.84) |
| ≥37 Weeks | 1.97 (1.96, 1.98) | 1.90 (1.88, 1.93) | 2.63 (2.62, 2.64) | 2.46 (2.44, 2.48) |
| **Term, Other Adverse[a]** | 1.19 (1.19, 1.20) | 1.21 (1.20, 1.21) | 1.26 (1.26, 1.27) | 1.27 (1.27, 1.28) |

AUC, area under the receiver operating characteristic curve; CI, confidence interval; RR, relative risk; PTB-ARIx, actionable risk index for preterm birth

[a]Includes individuals with spontaneous PTB, medically-indicated PTB, and PTB with an unknown subtype; PTBs with "preterm premature rupture of membranes" (PPROM), "preterm labor," or accompanied by evidence of tocolytic administration were classified as spontaneous PTB; PTBs without spontaneous PTB but with documentation of "medical induction," "assisted rupture of membranes," or cesarean delivery prior to 37 weeks, were considered medically-indicated; PTB without specific codes aligning with either spontaneous or provider-initiated PTB were classified as unknown subtype (see Supplemental Table 2 for specific coding).

**Figure 1.** Performance of the <20-week and ≥20-week actionable risk index (PTB-ARIx) in predicting early preterm birth (PTB, <32 weeks) by subtype[a] and co-occurrence with preeclampsia compared with term births without adverse outcomes[b] as measured by area under the receiver operating characteristic curve (AUC).

**A.** AUC = 0.713, 95% CI 0.704, 0.721; **B.** AUC = 0.774, 95% CI 0.762, 0.785; **C.** AUC = 0.812, 95% CI 0.803, 0.822; **D**. AUC = 0.745, 95% CI 0.737, 0.753; **E.** AUC = 0.880, 95% CI 0.872, 0.889; **F.** AUC = 0.965, 95% CI 0.963, 0.966

AUC, area under the receiver operating characteristic curve; PTB, preterm birth; PTB-ARIx, actionable risk index for preterm birth

[a]PTBs with "preterm premature rupture of membranes" (PPROM), "preterm labor," or accompanied by evidence of tocolytic administration were classified as spontaneous PTB; PTBs without spontaneous PTB but with documentation of "medical induction," "assisted rupture of membranes," or cesarean delivery prior to 37 weeks, were considered medically-indicated (see Supplemental Table 2 for specific coding).

[b]Term birth (≥ 37 weeks) without any of the following: early term birth (37–38 weeks), low birthweight (LBW; <2,500 grams), small-for-gestational-age birth (SGA; birthweight <10th percentile for gestational age and sex [195]), preeclampsia, "other placental problems" (placenta previa, placental abruption, or placenta accreta), SMM [194], major structural congenital anomaly in the infant, maternal death (<1 year postpartum), or infant death < 1 year (see Supplemental Table 2 for additional coding details).

**Figure 2.** Risk for preterm birth (PTB) by <20- and ≥20-week actionable risk index for PTB (PTB-ARIx) score by group in the training and testing samples.

PTB, preterm birth; PTB-ARIx, actionable risk index for preterm birth

**Figure 3.** Individuals with preterm birth (PTB), term birth with other adverse outcomes[a], or term birth without other adverse outcomes by <20- and ≥20-week actionable risk index for PTB (PTB-ARIx) score by group in the training and testing samples.

PTB, preterm birth; PTB-ARIx, actionable risk index for preterm birth

[a]Term birth (≥37 weeks) with any of the following: early term birth (37–38 weeks), low birth weight (LBW, <2,500 grams), small-for-gestational-age birth (SGA; birthweight <10th percentile for gestational age and sex [195]), preeclampsia, "other placental problems" (placenta previa, placental abruption, or placenta accreta), SMM [194], major structural congenital anomaly in the infant, maternal death (<1 year postpartum), or infant death < 1 year (see Supplemental Table 2 for additional coding details).

**Figure 4.** Risk of preterm birth (PTB) versus term birth without adverse pregnancy outcome[a] by <20- and ≥20-week

PTB, preterm birth; PTB-ARIx, actionable risk index for preterm birth; RR, relative risk
[a]Term birth (≥ 37 weeks) without any of the following: early term birth (37–38 weeks), low birthweight (LBW; <2,500 grams), small-for-gestational-age birth (SGA; birthweight <10th percentile for gestational age and sex [195]), preeclampsia, "other placental problems" (placenta previa, placental abruption, or placenta accreta), SMM [194], major structural congenital anomaly in the infant, maternal death (<1 year postpartum), or infant death < 1 year (see Supplemental Table 2 for additional coding details).
[b]Adjusted for number of prenatal visits grouped as <3, 3-6, 7-10, 11+ and coded as 1-4
[c]Where percent possibly mediated by prenatal visits calculated as (relative risk (RR) (unadjusted) – RR (adjusted)) / (RR (unadjusted – 1)) × 100.